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Abstract
Apoptosis is known to contribute to the loss of neurological function in brain injury
and several neurodegenerative diseases. The Bcl-2 family of proteins consist of pro-apoptotic
and anti-apoptotic members that interact physically and functionally to regulate apoptosis in
a cell type and stimulus specific manner. We have previously demonstrated that the Bcl-2
family member Puma plays a key role in triggering neuronal apoptosis under diverse stress
conditions. However, the mechanism by which Puma mediates apoptosis remains unclear.
Here we found that Puma contains two domains required for its apoptotic function: the BH3
domain and a region in the c-terminus that regulates its localization to the mitochondria. We
found that the BH3 domain is required to bind both the anti-apoptotic protein, Bcl-xl, and the
pro-apoptotic protein, Bax. However, we found that the BH3 domain of the protein is not
required for its mitochondrial-localization. Instead, we identified a region within the cterminus of Puma that is essential for both mitochondrial-localization and apoptotic function
of the protein. Although we found that the c-terminus of Puma is not required to bind Bcl-xl
or Bax in vitro, it is required for co-localization and likely interaction with these proteins in
the cellular context. In summary, we determined that Puma requires both its c-terminal
mitochondrial-localization sequence and its BH3 domain to co-localize with and bind to Bcl2 family members, and to induce neuronal cell death.
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Preface
Apoptosis plays an crucial role in normal development and maintenance of tissue
homeostasis. It is required to eliminate unnecessary tissue during development, and later on
in an organism's lifespan it is necessary to destroy damaged or mutated cells (Kerr et al.
1972; Oppenheim 1991; Yoshida et al. 1998). One of the reasons that apoptosis is utilized
for these functions is that unlike other modes of cell death, such as necrosis, apoptosis
eliminates cells without eliciting an inflammatory response or causing damage to the
surrounding tissue (Kerr et al. 1972). Disruption of the normal apoptotic process in animal
models has been shown to cause significant and often lethal defects (Ashkenazi & Dixit
1998; Li et al. 2000; Motoyama et al. 1995; Strasser et al. 1990; Yoshida et al. 1998).
Perhaps due to its vital role in normal tissue, dysregulation of the apoptotic process
also plays a major role in many diseases. Many cancer cells contain mutations in the
apoptotic machinery that allow them to continue to grow when they would otherwise die
(Adams & Cory 2007; Cory et al. 1999; Strasser et al. 1990; Yu & Zhang 2009; Vaux et al.
1988). Activation of apoptosis by acute trauma, as in ischemic injury or spinal cord injury,
can result in significant neuronal loss (Engel et al. 2011; Kotipatruni et al. 2011; Nitatori et
al. 1995; Steckley et al. 2007). Apoptotic cell death also plays a significant role in many
neurodegenerative conditions, including Alzheimer's disease, Parkinson's disease, and
Huntington's disease (Higgins et al. 2010; Portera-Cailliau et al. 1995; Vila & Przedborski
2003). Because it plays such a crucial role in both healthy and diseased tissue, a more
complete understanding of the key proteins involved in the regulation of apoptosis will be
important for the development of new treatments applicable to a variety of injury and disease
conditions.
ix
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Chapter 1 – Introduction
1.1 – Apoptosis
Apoptosis, or programmed cell death, is perhaps the most prevalent and wellregulated means of cell death. The cell must precisely coordinate the actions of many
proteins in order to destroy itself without causing damage to surrounding cells. This
precise coordination presents a distinctly identifiable cellular morphology. In the initial
stages of apoptosis, the cellular membrane shrinks and develops a rounded appearance
(Kerr et al. 1972). At the same time, the chromatin condenses in the now shrinking
nucleus, in a process termed pyknosis (Kerr et al. 1972). The cellular membrane then
takes on the blebbed appearance characteristic of apoptotic cells (Kerr et al. 1972). In the
final stage of apoptosis, the cell packages its remaining contents into small vesicles,
known as apoptotic bodies, that can be easily engulfed by phagocytic cells for
degradation (Kerr et al. 1972).
This carefully contained process can be triggered by both extracellular (extrinsic
pathway) and intracellular (intrinsic pathway) cues. In the extrinsic apoptotic pathway,
extracellular ligands bind to death receptors on the cellular surface in order to activate
apoptosis (Ashkenazi & Dixit 1998). In the intrinsic apoptotic pathway, cellular stress
causes expression or activation of apoptosis-inducing factors (Ashkenazi & Dixit 1998;
Cory & Adams 2002). These factors activate pro-apoptotic members of the B-cell
lymphoma 2 (Bcl-2) family and result in the permeabilization of the mitochondrial
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membrane (Cory & Adams 2002). The primary focus of this thesis is the intrinsic
apoptotic pathway.

1.11 - Intrinsic apoptotic pathway
The intrinsic apoptotic pathway is activated by many different cellular stressors,
including but not limited to: genotoxic, endoplasmic reticulum (ER), and oxidative stress
(Engel et al. 2011; Galehdar et al. 2010; Reimertz et al 2003; Steckley et al. 2007). The
B-cell lymphoma 2 (Bcl-2) family of proteins plays a key role in the regulation of the
intrinsic apoptotic pathway, and downstream caspases are primarily responsible for the
execution of the apoptotic process (Cory & Adams 2002; Salvesen & Dixit 1997).
Activation of the pro-apoptotic Bcl-2 family members results in mitochondrial outer
membrane permeabilization and releases pro-death factors, such as cytochrome-c, into
the cytoplasm (Figure 1; Cory & Adams 2002; Li et al. 1997; Yoshida et al. 1998). Once
released into the cytoplasm, cytochrome-c forms a complex with apoptosis proteaseactivating factor 1 (APAF-1) and caspase-9 known as the apoptosome (Figure 1; Li et al.
1997; Liu et al. 1996). The apoptosome cleaves and thereby activates caspase-9, which
then cleaves and activates the downstream effector caspases, caspase-3 and caspase-7
(Figure 1; Li et al. 1997). This caspase cascade is responsible for the characteristic
apoptotic events, including: chromatin condensation and fragmentation, membrane
blebbing, and packaging of cellular remains into apoptotic bodies (Cory & Adams 2002;
Liu et al. 1997).
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Figure 1 - The Intrinsic Apoptotic Pathway. The intrinsic apoptotic pathway is
activated by a variety of cell stressors, including oxidative and genotoxic stress. These
stressors trigger the up-regulation or activation of pro-apoptotic BH3-only Bcl-2 family
members, which act both by inhibiting the anti-apoptotic family members and by
activating the multi-domain pro-apoptotic family members. This allows the multidomain Bcl-2 family members to translocate the the mitochondrial outer membrane,
where they oligomerize and form channels that allow the release of pro-death factors
into the cytoplasm. In the cytoplasm, these factors interact with caspase-9 in a
structure called the apoptosome. The apoptosome cleaves and activates caspase-9,
which goes on to activate downstream effector caspases, caspase-3 and caspase-7.
These downstream effector caspases trigger the cellular changes characteristic of
apoptotic cell death, such as chromatin condensation and membrane blebbing.
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1.2 - Bcl-2 Family Members
The B-cell lymphoma 2 (Bcl-2) family of proteins are key regulators of the
intrinsic apoptotic pathway (Cory & Adams 2002; Engel et al. 2011). These proteins
share one or more Bcl-2 homology (BH) domains with their namesake, Bcl-2. Although
they have different amino acid sequences and contain different BH domains, their threedimensional fold structures are strikingly similar. Most Bcl-2 family members have two
central hydrophobic alpha-helices surrounded by six or seven amphipathic alpha-helices
(Petros et al. 2004). This similarity in structure may help to explain their ability to form
homo and hetero-dimers with other family members (Petros et al. 2004).
The Bcl-2 family members are divided based on their functions into two main
categories: the pro-apoptotic family members and the anti-apoptotic family members
(Cory & Adams 2002). The pro-apoptotic family members are further sub-divided into
Bcl-2 homology domain three (BH3) only proteins and multi-BH domain proteins (Cory
& Adams 2002). Altering the expression or activation of one of the family members can
kill cells or render them resistant to apoptotic cell death (Cory et al. 1999; Motoyama et
al. 1995; Strasser et al. 1990; Steckley et al. 2007).
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Figure 2 - Bcl-2 Family Members. The Bcl-2 family of proteins are important
regulators of the intrinsic apoptotic pathway. They are divided functionally into antiapoptotic and pro-apoptotic proteins and the latter group is further subdivided into multidomain and BH3 domain-only proteins. The BH3-only proteins promote apoptosis by
activating the multi-domain pro-apoptotic proteins, while the anti-apoptotic proteins
inhibit both the BH3-only and multi-domain proteins to suppress apoptosis.
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1.21 - Pro-apoptotic Bcl-2 Family Members
As suggested by their name, the pro-apoptotic members of the Bcl-2 family of
proteins act to promote apoptosis. They are subdivided into BH3-only proteins and
multi-domain proteins. The BH3-only proteins have only their BH3 domain in common
with Bcl-2 and are the first response to cellular stress (Engel et al. 2011). Expression and
activation of the BH3-only proteins results in the activation of the multi-domain Bcl-2
family members (Engel et al. 2011). The multi-domain Bcl-2 proteins share between one
and three of the Bcl-2 homology domains and act by forming channels in the
mitochondrial outer membrane and allowing the release of of pro-death factors, such as
cytochrome-c (Cory & Adams 2002; Lalier et al. 2007; Li et al. 1997).

1.211 - BH3-only Bcl-2 family members
The BH3-only members of the pro-apoptotic Bcl-2 proteins consist of: Puma,
Noxa, Bid, Bim, Bad, Bmf, and Hrk (Cory & Adams 2002; Engel et al. 2011). Although
they are structurally similar, the BH3-only proteins are regulated by diverse mechanisms.
Some, such as Puma, are regulated mainly through transcription; others, such as Bid, are
regulated mainly post-transcriptionally via proteolytic cleavage (Cory & Adams 2002;
Engel et al. 2011). Their affinity for binding to the anti-apoptotic proteins is also quite
diverse; some BH3-only proteins, such as Noxa and Bid, are able to bind to only some of
the anti-apoptotic proteins, whereas others, such as Puma, are able to bind to all of the
anti-apoptotic proteins (Kuwana et al. 2005; Uren et al. 2007). The BH3-only proteins
are differentially activated by various stimuli and in various cell types; one BH3-only
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protein that is highly efficacious and of almost universal importance is Puma (Cory &
Adams 2002; Engel et al. 2011; Hikisz et al. 2012).
In accordance with their name, the BH3-only proteins contain only the third of the
Bcl-2 homology domains. It is a short, alpha-helical, amphipathic domain approximately
9-16 amino acids long (Adams & Cory 1998; Chittenden et al. 1995; Cory & Adams
2002; Engel et al 2011). The BH3 domain is the site of protein interactions (the binding
site for either anti-apoptotic or multi-domain proapoptotic Bcl-2 family members) and is
required for the apoptotic activity of BH3-only proteins (Chittenden et al. 1995; Engel et
al. 2011; Kazi et al. 2011; Kelekar & Thompson 1998; Liu et al. 2009).
Two main mechanisms of action have been proposed for these proteins: the direct
activation model and the indirect activation model. In the direct activation model, one of
the BH3-only proteins directly binds to and activates one of the multi-BH domain proapoptotic Bcl-2 family members (Chipuk & Green, 2008; Cory & Adams, 2002; Engel et
al. 2011). In the indirect activation model, a BH3-only protein binds to one of the antiapoptotic family members and displaces a multi-BH domain pro-apoptotic Bcl-2 family
member (Chipuk & Green 2008; Cory & Adams, 2002; Engel et al. 2011). Once the
multi-BH domain pro-apoptotic Bcl-2 family member is freed from the anti-apoptotic
protein, a few methods of activation have been suggested. Some believe that once
released, the proteins can bind to membrane-bound, otherwise activated multi-BH
domain pro-apoptotic Bcl-2 family members and form oligomers (Kazi et al. 2011;
Valentijn 2008). Others have proposed that as-yet-unidentified intermediary proteins
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bind directly to the multi-BH domain pro-apoptotic Bcl-2 family members once they are
released from the anti-apoptotic proteins (Cory & Adams 2002). It has also been
suggested that the binding and release of multi-BH domain pro-apoptotic Bcl-2 family
members from anti-apoptotic proteins may in itself be sufficient to activate them (Gautier
et al. 2011; Moreau et al. 2003).
There is evidence for both models, and it seems most likely that each of the BH3only proteins functions slightly differently, allowing the cell to precisely regulate
apoptosis. Some BH3 proteins, such as Bid, are widely accepted as direct activators of
multi-BH domain pro-apoptotic Bcl-2 family members (Desagher et al. 1999; Eskes et
al. 2000; Lovell et al. 2008). Others, such as Bad, appear to function only through the
indirect model (Lalier et al. 2007). The conflicting evidence for other BH3-only proteins,
such as Puma (Gallenne et al 2009; Gautier et al. 2011; Ming et al. 2006; Willis et al.
2007), may indicate that they function via a combination of both the indirect and direct
activation models (Du et al. 2011; Engel et al. 2011; Kuwana et al. 2005; Steckley et al.
2007; Zhang et al. 2009).

1.212 - Multi-BH domain Bcl-2 family members
There are three multi-BH domain members of the pro-apoptotic Bcl-2 proteins:
Bax, Bak, and Bok (Adams & Cory 1998; Cory & Adams, 2002). They contain the first
three BH domains: BH1, BH2, and BH3 (Cory & Adams, 2002; Petros et al. 2004).
Structurally, they consist of two core hydrophobic alpha-helices surrounded by seven
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amphipathic alpha-helices (Petros et al. 2004). This structure allows them to exist in one
conformation in the cytosol and to form oligomeric channels in the mitochondrial outer
membrane when activated (Chipuk & Green 2008; Lalier et al. 2007).
Bax, Bak, and Bok are typically activated by the BH3-only proteins, either
through a direct or an indirect interaction (Chipuk & Green 2008). Once activated, they
oligomerize and form channels in the outer mitochondrial membrane (Cory & Adams
2002; Lalier et al., 2007). These channels permeabilize the outer mitochondrial
membrane and allow the release of pro-apoptotic factors, such as cytochrome-c, into the
cytoplasm. When released into the cytoplasm, these pro-death factors are free to cleave
and activate caspase-9 (Cory & Adams 2002; Li et al. 1997). Once activated, caspase-9
activates downstream caspases, resulting in apoptotic cell death (Li et al. 1997; Liu et al.
1996).

1.22 - Anti-apoptotic Bcl-2 Family Members
The anti-apoptotic Bcl-2 family members consist of: Bcl-xl, Bcl-2, Bcl-w, A1,
and Mcl-1 (Adams & Cory 1998; Cory & Adams 2002). They contain all four of the BH
domains as well as a c-terminal membrane-localization sequence (Lindsay et al. 2011;
Petros et al. 2004; Reed et al. 1996). Their three-dimensional structure consists of two
hydrophobic alpha-helices surrounded by five amphipathic alpha-helices (Petros et al.
2004). The first three BH domains form a hydrophobic binding pocket that is responsible
for the interactions between anti-apoptotic proteins and other Bcl-2 family members
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(Petros et al. 2004; Sattler et al. 1997). Some of the anti-apoptotic family members have
also been shown to form soluble homodimers in the cytoplasm by sequestering their cterminal membrane-localization sequence in this hydrophobic pocket until activated
(Jeong et al. 2004; Petros et al. 2004).
Anti-apoptotic Bcl-2 family proteins function primarily by binding to and
restricting both the BH3-only and multi-domain pro-apoptotic Bcl-2 family members.
When anti-apoptotic proteins bind to the BH3-only proteins, it prevents them from
binding to and/or activating the multi-domain pro-apoptotic Bcl-2 family members
(Nakano & Vousden 2001; Steckley et al. 2007; Yu et al. 2001). When anti-apoptotic
Bcl-2 proteins bind to the multi-domain pro-apoptotic Bcl-2 family members, it prevents
the activation and/or oligimerization of the multi-BH domain pro-apoptotic proteins
(Gallenne et al. 2009; Gautier et al. 2011; Jeong et al. 2004; Sattler et al. 1997).

1.3 – Bcl-2 family members in neuronal apoptosis
The wide variety of apoptotic regulators seems to suggest that each protein may
be of differing importance in various cell types and for various cell-death stimuli. There
is growing evidence to indicate that different cell types may regulate apoptosis in distinct
ways (Chen et al. 2005; Chipuk et al. 2010; Cory & Adams 2002; Engel et al. 2011;
Hikisz et al. 2012; Kim et al. 2006; Kuwana et al. 2005; Letai et al. 2002). For this
reason it is increasingly important to determine the roles of the Bcl-2 family proteins in
each cell type and under each apoptotic stimulus. Apoptosis has been shown to play an
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important role in a number of neurodegenerative disorders including Alzheimer's and
Huntington's disease, as well as in acute conditions, such as stroke and traumatic brain
injury (Engel et al. 2011; Higgins et al. 2010; Portera-Cailliau 1995; Vila & Przedborski
2003). The Bcl-2 family of proteins appears to play an important role in the regulation of
neuronal apoptosis under these conditions (Boise et al. 1993; Frankowski et al. 1995;
Galehdar et al. 2010; Kotipatruni et al. 2011; Rubin et al. 1994; Steckley et al. 2007).
Anti-apoptotic members of the Bcl-2 family have been shown to inhibit neuronal
cell death induced by a number of different stimuli, including: neurotrophic factor
withdrawal, reactive oxygen species, and ischemia (Allsopp et al. 1993; Garcia et al.
1992; Martinou et al. 1994; Zhong et al. 1993). Of the anti-apoptotic Bcl-2 family
members, Bcl-xl appears to play a particularly important role in preventing neuronal
apoptosis (Boise et al. 1993; Frankowski et al. 1995; Rubin et al. 1994).
Of course, the role of the pro-apoptotic members of the Bcl-2 family in neuronal
apoptosis cannot be neglected. The multi-domain pro-apoptotic Bcl-2 family member,
Bax, has been shown to mediate neuronal apoptosis in a rat model of spinal cord injury
(Kotipatruni et al. 2011), and neuronal apoptosis induced by oxidative stress (Steckley et
al. 2007). The pro-apoptotic BH3-only protein, Puma, has been shown to be of
particular importance in neuronal death induced by a number of factors, including:
trophic factor deprivation, endoplasmic reticulum stress, ischemia, and oxidative stress
(Ambacher et al. 2012; Galehdar et al. 2010; Niizuma et al. 2009; Reimertz et al. 2003;
Steckley et al. 2007). It appears that the members of the Bcl-2 protein family are key
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regulators of neuronal apoptosis in a number of conditions, both chronic (as in the case of
neurodegenerative disorders) and acute (as with stroke or spinal cord injury).
The Bcl-2 family of proteins has also been shown to play a crucial role in the
regulation of neuronal apoptosis during development. Anti-apoptotic Bcl-2 family
members are highly expressed in developing neurons (Abe-Dohmae 1993; Frankowski et
al. 1995). Bcl-xl knockout mice show increased neuronal apoptosis (Motoyama et
al.1995) that can be mitigated by also knocking out the pro-apoptotic protein, Bax
(Shindler et al. 1997). The pro-apoptotic members of the Bcl-2 family also play an
important role in normal neuronal development. Bax/Bak double knockout mice have a
number of neurological deficits, including apparent deafness and seizures (Lindsten et al.
2000). Histologically, the brains of these mice display accumulations of small,
undifferentiated neuronal cells, most notably in the periventricular area, the
hippocampus, the cerebellum, and the olfactory bulb; all regions where neural stem cells
are common (Lindsten et al. 2000). Bax knockout mice show decreased sympathetic and
neuronal apoptosis during development and are resistant to neuronal apoptosis induced
by trophic factor deprivation (Deckwerth et al. 1996). The Bcl-2 family of proteins is
also critical in maintaining tissue homeostasis by preventing the accumulation of
damaged or dysfunctional cells (Adams & Cory 2007; Cory et al. 1999; Cory & Adams
2002). The pro-apoptotic members of the Bcl-2 family, most notably Puma, are activated
by oncogenic stress in order to safely eliminate cancerous and potentially cancerous cells
(Dudgeon et al. 2010; Ming et al. 2006; Yu et al. 2001; Yu et al. 2003). The
accumulated evidence indicates that the Bcl-2 family of proteins play a crucial role in the
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regulation of neuronal apoptosis, both during development and for maintenance of
homeostasis.

1.4 - p53 Up-regulated Mediator of Apoptosis (Puma)
p53 up-regulated mediator of apoptosis (Puma) is perhaps the most prevalent and
effective of the BH3-only Bcl-2 family members. Puma has been shown to play an
essential role in apoptosis induced by many different factors, including: oxidative stress,
genotoxic stress, endoplasmic reticulum (ER) stress, trophic-factor withdrawal, and
oncogenesis (Ambacher et al. 2012; Engel, T et al. 2011; Galehdar et al. 2010; Niizuma
et al 2009; Reimertz et al. 2003; Steckley et al. 2007). Although other BH3-only
proteins appear to contribute to neuronal apoptosis in some of these conditions, none of
them are as universally essential as Puma. Even under conditions where other BH3-only
proteins are expressed, Puma still seems to be the essential factor for apoptosis to occur
(Ambacher et al. 2012; Galehdar et al. 2010; Niizuma et al 2009; Reimertz et al. 2003;
Steckley et al. 2007).
Puma was identified by several independent groups at almost the same time (Han
et al. 2001; Nakano & Vousden 2001; Yu et al. 2001). As suggested by its name, Puma
is transcriptionally up-regulated by the apoptotic protein p53 (Cregan et al 2004; Nakano
& Vousden 2001; Yu et al. 2001), although it has also been shown to be induced
independently of p53 expression (Wu et al. 2007; Yu & Zhang 2009). Other
transcriptional regulators of Puma have been identified, including p73 (Ming et al. 2008;
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Ray et al. 2011), FoxO3a (Dudgeon et al. 2010; You et al. 2006), CHOP (Galehdar 2010;
Wu et al. 2007), E2F1 (Hershko & Ginsberg 2004; Ray et al. 2011), and c-Myc
(Fernandez et al. 2003). This variety of regulators allows Puma expression to be
controlled specifically in different cell types and under different forms of cell stress.
Puma is present at very low levels in healthy cells and is transcribed when the cell
experiences a wide variety of stressors (Nakano & Vousden 2001; Puthalakath & Strasser
2002; Yu et al. 2001). The transcriptional up-regulation of Puma has been widely
accepted as its main form of regulation, but recent evidence suggests that it may also be
post-transcriptionally regulated by phosphorylation (Fricker et al. 2010; Lam et al. 2009;
Puthalakath & Strasser 2002; Sandow et al. 2012). Phosphorylation of Puma at serineten has been shown to target the protein for degradation and reduce Puma-induced
apoptosis (Fricker et al.2010; Sandow et al. 2012). Although other phosphorylation sites
have been identified, their function in regulating Puma has not yet been determined
(Hikisz & Kilianska 2012; Fricker et al. 2010; Lam et al. 2009; Puthalakath & Strasser
2002; Sandow et al. 2012).
There are two main splice-variants of Puma produced by cells: Puma-α and
Puma-β (Nakano & Vousden 2001; Yu et al. 2001). Initially, these variants were thought
to produce proteins that were similar in size and structure, both of which had full proapoptotic activity (Nakano & Vousden 2001; Yu et al. 2001). However, recent evidence
has emerged to suggest that Puma-β may be smaller than Puma-α and lack full apoptotic
activity (Tampio et al. 2009). Other splice-variants of Puma also exist, some of which
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transcribe proteins without the BH3 domain or the full length c-terminus (Nakano &
Vousden 2001; Yu et al. 2001). These proteins lack the apoptotic activity of full-length
Puma and their cellular function is unknown, though perhaps also negligible because they
are produced at such low levels (Nakano & Vousden 2001; Yu et al. 2001).
Like the other BH3-only proteins, Puma contains a BH3 domain that is required
for its interaction with other Bcl-2 family members (Day et al. 2008; Nakano & Vousden
2001; Yu et al. 2001). It is amphipathic and alpha-helical in structure, spanning amino
acids 137 to 150 of the protein (Day et al. 2008). The BH3 domain of Puma also has a
similar function to the BH3 domains of the other BH3-only proteins; it is required to bind
to the anti-apoptotic Bcl-2 proteins, Bcl-xl, Bcl-2, Bcl-w, A1, and Mcl-1 (Day et al.
2008; Gautier et al. 2011; Nakano & Vousden 2001; Yu et al. 2001). The BH3 domain
of Puma is the site of Puma's putative direct interaction with the multi-BH domain proapoptotic Bcl-2 family members. The BH3 domains of Bid and Bim, two of the other
BH3-only proteins, have been shown to interact directly with the multi-BH domain proapoptotic protein, Bax (Kuwana et al. 2005; Lovell et al. 2008). Many groups have
found evidence that the BH3 domain of Puma can directly bind to and activate Bax in the
same manner (Cartron et al. 2004; Du et al. 2011; Gallenne et al. 2009; Steckley et al.
2007; Yee & Vousden 2008; Zhang et al. 2009). However, unlike the other members of
the Bcl-2 family, Puma does not contain a classic c-terminal membrane localization
sequence (Nakano & Vousden 2001; Yee & Vousden 2008; Yu et al. 2001; Yu et al.
2003). Puma has been shown to localize to the mitochondria, but the amino acids
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involved and their exact function have not been well-defined (Hikisz & Kilianska 2012;
Nakano & Vousden 2001; Yee & Vousden 2008; Yu et al. 2001).
The reasons for the importance of Puma in cellular apoptosis are currently
unclear. It has been suggested that the reason for Puma's efficacy is its ability to bind all
of the anti-apoptotic family members, or that Puma may bind with greater strength than
the other Bcl-2 family members (Chen et al. 2005; Kuwana et al. 2005; Yu & Zhang
2009). One important difference between Puma and the other BH3-only proteins is that
Puma can bind directly to all of the anti-apoptotic Bcl-2 family members with high
affinity (Chen et al. 2005; Kuwana 2005). This is likely part of the reason that Puma is
such an efficacious and important protein in neuronal apoptosis. However, even these
ideas fail to explain what it is about Puma that enables it to be such an effective and
essential mediator of apoptosis.

1.5 – Bcl-2-associated x protein (Bax)
Bcl-2-associated x protein (Bax) is a multi-domain pro-apoptotic Bcl-2 family
member. Similar in structure to the other Bcl-2 family members, Bax consists of two
hydrophobic alpha-helices surrounded by seven amphipathic alpha-helices (Lalier et al.
2007; Petros et al. 2004; Suzuki et al. 2000). Like the other multi-domain pro-apoptotic
members of the Bcl-2 family, Bax contains three BH domains: BH1, BH2, and BH3
(Petros et al. 2004; Suzuki et al. 2000). Several regions of Bax have been shown to be
important for the function of the protein: the BH3 domain; the first alpha-helix (Hα1); the

19
central helices, Hα5 and Hα6; the n-terminus; and the c-terminus (Carton et al. 2004;
Lalier et al. 2007; Reed et al.1996; Suzuki et al. 2000; Wolter et al. 1997).
The number of important domains in Bax is unsurprising, considering the overall
significance of the protein in apoptosis. Our lab and others have shown that Bax plays a
particularly important role in Puma-mediated neuronal apoptosis (Engel et al, 2011;
Shindler et al. 1997; Steckley et al. 2007). Under normal conditions, Bax is present in
the cellular cytoplasm in an inactive conformation. Upon activation, Bax translocates to
the mitochondrial outer membrane (MOM) and forms homo- or hetero-oligomers with
other Bax proteins or with Bak. These oligomers act as channels in the MOM and allow
the release of cytochrome-c and other death factors into the cytoplasm.
Like most of the BH3 domains found in Bcl-2 family members, the BH3 domain
of Bax has been implicated in its interactions with other Bcl-2 family proteins. A peptide
modeled on the BH3 domain of Bax has been shown to interact with the hydrophobic
binding pocket on the anti-apoptotic proteins, Bcl-xl and Bcl-2; the same peptide also
interferes with Bax binding to Bcl-xl and Bcl-2 (Moreau et al. 2003). Mutations of the
BH3 domain of Bax appear to interfere with its ability to bind Bcl-xl, Bcl-2, and Mcl-1
(Cartron et al. 2004; Wang et al. 1998). The Bax BH3 region also seems to be necessary
for its interaction with and activation by the pro-apoptotic BH3-only protein, Bad
(Cartron et al. 2004). However, the BH3 region of Bax does not appear to be responsible
for all of its interactions with Bcl-2 family members.

20
Indeed, the BH3-only proteins Puma and Bid appear to interact with Bax via its
Hα1 domain rather than its BH3 domain (Cartron et al. 2004). The first alpha helix at the
n-terminus of Bax, Hα1, is one of the amphipathic helices sequestered in the unactivated,
cytoplasmic conformation of the protein. It has been suggested that the exposure of the
Hα1 domain may be a critical step in the activation and conformational change of Bax
(Lalier et al. 2007). The aspartate at position 33 of Bax is required for Bax to interact
with the BH3 regions of Bid and Puma; mutation of this acidic residue into a neutral
residue, alanine, abrogates these interactions (Cartron et al. 2004). However, the Hα1
domain of Bax is not required for its interactions with Bcl-xl and Bcl-2, and mutation of
the Hα1 domain does not affect the ability of Bax to bind the anti-apoptotic proteins Bclxl and Bcl-2 (Cartron et al. 2004).
Although they do not appear to play a role in protein interactions, the central
helices of Bax, Hα5 and Hα6, are important for the pro-apoptotic function of the protein.
These central hydrophobic alpha-helices are tightly-sequestered in the inactive
cytoplasmic conformation of Bax, but are exposed upon its activation (Lalier et al. 2007;
Suzuki et al. 2000). Their resemblance to the pore-forming domains of diptheria toxin
and colicins inspired research into their potential for a similar function in Bax (Nouraini
et al. 2000). Structurally, Hα5 and Hα6 of Bax appear to be trans-membrane domains;
peptides based on these helices have been shown to form pores in a synthetic lipid
membrane (Annis et al. 2005; Garcia-Saez et al. 2006). Although Hα5 and Hα6 are
required to form the channel in the mitochondrial outer membrane that allows activated
Bax to release pro-apoptotic factors into the cytoplasm, they do not appear to regulate its
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localization to the mitochondria (Carton et al. 2005; Lalier et al. 2007). Instead, the
localization of Bax appears to be regulated by both its c-terminus and its n-terminus.
At the c-terminus of Bax, its ninth alpha-helix, Hα9, occupies the hydrophobic
binding pocket formed by the first three BH domains of Bax in its inactive conformation
(Suzuki et al. 2000). Activation of Bax exposes this helix, which resembles the cterminal membrane-localization domains in Bcl-xl and Bcl-2 (Lalier et al. 2007). The cterminus of Bax has been shown to play an important role in the localization and function
of the protein (Gardia et al. 2004; Nechustan et al. 1999). However, some studies have
demonstrated that Bax retains its ability to translocate to the mitochondria despite cterminus deletion (Antonsson et al. 2000; Carton et al. 2003). Perhaps this is because the
n-terminus of Bax also appears to play a role in the mitochondrial-localization of the
protein (Carton et al. 2003). The n-terminus of Bax has been shown to contain a
mitochondrial-localization sequence, and deletion of this sequence has been shown to
abrogate its localization (Carton et al. 2003). Interestingly, the first 20 amino acids of
Bax appear to inhibit its mitochondrial-localization, and have been termed the Apoptosis
Regulating Target (ART) domain (Goping et al. 1998). Deletion of this domain results in
a protein constitutively localized to the mitochondria (Goping et al. 1998). However, the
complete n-terminus alone is unable to insert into the mitochondrial outer membrane
(Carton et al. 2003). It appears that the n-terminus and the c-terminus of Bax co-operate
to regulate the localization of the protein (Lalier et al. 2007).
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Mitochondrial localization is of particular importance in the apoptotic function of
Bax. Without its ability to localize to the mitochondrial outer membrane, Bax cannot
induce apoptosis. The precise reasons for the importance of membrane-localization in
the apoptotic function of Bax are still a subject of investigation, but some recent studies
have suggested a role for the membrane in protein interactions (Bogner et al. 2010;
Lalier, L. et al. 2007, Lovell, J.F. et al. 2008; Roucou et al. 2002; Yethon et al. 2003).
The BH3-only protein, tBid, requires the presence of a membrane in order to bind to and
activate Bax (Lovell, J.F. et al. 2008). It has been suggested that contact with the
membrane may open the conformation of Bax and encourage protein interactions
(Yethon et al. 2003), or that mitochondrial proteins may play a role in Bax
oligomerization (Roucou et al. 2002). Of course, in order for Bax to form the channels in
the mitochondrial outer membrane that are required for release of pro-apoptotic factors
into the cytoplasm, it must be in the mitochondrial outer membrane. The mitochondriallocalization of Bax plays an essential role in the apoptotic function of the protein.
Bax is constitutively expressed in cells in its inactive form and is regulated posttranscriptionally by interactions with the pro-apoptotic BH3-only proteins as well as the
anti-apoptotic members of the Bcl-2 family (Lalier et al. 2007). Bax has two major
conformations: a cytosolic, inactive conformation and a membrane-bound, active
conformation (Lalier et al. 2007; Wolter et al. 1997). These two conformations have
been dubbed CLIC (for Cytosolic Locked In Conformation) and CLAC (for Cytochromec Liberation Associated Conformation) for easier reference (Lalier et al. 2007).
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In its cytosolic conformation, Bax is tightly-packed and the regions responsible
for protein interaction and membrane-localization are sequestered within the structure of
the protein. The three BH domains of Bax form a hydrophobic binding pocket, similar to
the one seen in the anti-apoptotic proteins Bcl-2 and Bcl-xl, that facilitates the binding of
other Bcl-2 family members via the BH3-domain (Jeong et al. 2004; Suzuki et al. 2000).
When in its cytosolic conformation, the ninth alpha-helix of Bax (Hα9), at the c-terminus
of the protein, occupies the hydrophobic binding pocket formed by the three BH3
domains (Suzuki et al. 2000). This interaction effectively sequesters two important
regions of Bax: the BH3 domain and the c-terminus. Occupation of the hydrophobic
binding pocket, and specifically of the BH3 domain, deters protein interactions;
sequestration of the c-terminus prevents Bax from anchoring in the mitochondrial outer
membrane (Suzuki et al. 2000; Lalier et al. 2007). The third region of importance for the
function of Bax, the Hα1 helix at the n-terminus of the protein, forms bonds with the
hydrophobic helices at the centre of the protein and acts to stabilize the protein structure
in its cytoplasmic conformation (Suzuki et al. 2000; Lalier et al. 2007). CLIC Bax is a
closely-packed protein unlikely to interact with other proteins or membranes. In order for
Bax to promote apoptosis, it must be changed into its active conformation so that it is
able to both insert into membranes and bind to other proteins.
There are two proposed models of Bax activation by BH3-only pro-apoptotic
proteins: the indirect and the direct model of Bax activation. In the direct activation
model, BH3-only proteins directly interact with Bax in order to alter its conformation and
activate the protein (Figure 3; Cartron et al. 2004; Du et al. 2011). Interactions have
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been shown to occur between the BH3 domain of some BH3-only proteins and the Hα1
domain of Bax (Carton et al. 2004). It is believed that a BH3-only protein binding to the
Hα1 domain of Bax may open up the structure of the protein and encourage the switch to
its active conformation (Carton et al. 2004). There is an extensive body of evidence to
show that Bid, one of the BH3-only proteins, can directly interact with and activate Bax
in order to promote apoptosis (Billen et al. 2009; Eskes et al. 2000; Lovell et al. 2008).
Bid appears to require a membrane in order to bind to and activate Bax (Lovell et al.
2008; Veresov & Davidovskii 2009). Upon binding to the mitochondrial outer
membrane, Bid is able to bind and activate Bax, which then inserts into the mitochondrial
outer membrane and forms oligomeric channels (Lovell et al. 2008; Veresov &
Davidovskii 2009). Many studies have also shown that Puma can directly activate Bax in
a manner similar to Bid (Cartron et al. 2004; Du et al. 2011; Melino et al. 2004; Ren et
al. 2010). In the indirect model, BH3-only proteins activate Bax through a variety of
proposed mechanisms, such as the inhibition of anti-apoptotic Bcl-2 family proteins
(Kazi et al. 2010; Willis et al.2007). The indirect activation of Bax by BH3-only proteins
has been explained by three slightly different sub-models: the sensitizer model, the
derepressor model, and the neutralization model (Figure 3; Chipuk et al. 2010; Kazi et al.
2011; Kuwana et al. 2005; Ming et al. 2006; Uren et al. 2007; Willis et al. 2007). In
each of these models, the indirect activators interact directly with anti-apoptotic proteins
in order to activate Bax. Evidence has been given for both the indirect and the direct
activation models; it has also been suggested that the activation of Bax may be regulated
by a combination of the two models, or that different BH3-only proteins may follow
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different models (Juin et al. 2005; Kim et al. 2006; Kuwana et al. 2005; Letai et al.
2002). The ability of the various BH3-only proteins to induce apoptosis via the different
models of Bax activation may help to explain the differences in their efficacy.
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Figure 3 - Bax Activation Models. (a) Direct activation model: Direct activator BH3only proteins, such as Bid and perhaps Puma, bind directly to the Hα1 domain of Bax via
their BH3 domain; this switches Bax into its active conformation (Cartron et al. 2004;
Du et al. 2011; Eskes et al. 2000; Lalier et al. 2007). (b) Sensitizer model: Indirect
activator BH3-only proteins sequester anti-apoptotic proteins so that they cannot inhibit
direct activator BH3-only proteins; this leaves direct activator BH3-only proteins free to
activate Bax (Chipuk et al. 2010; Willis et al. 2007). (c) De-repressor model: Direct
activator proteins are bound to anti-apoptotic proteins in cytoplasm. Indirect activator
BH3-only proteins compete with direct activator BH3-only proteins for binding to antiapoptotic proteins; this releases direct activator BH3-only proteins so they are free to
activate Bax (Chipuk et al. 2010; Chipuk et al. 2008; Kuwana et al. 2005). (d)
Neutralization model: Bax is bound to anti-apoptotic proteins in the cytoplasm. Indirect
activator proteins compete with Bax for binding to these anti-apoptotic proteins; this
frees and, in the process, activates Bax (Chipuk et al. 2010; Gautier et al. 2011; Kazi et
al. 2011; Ming et al. 2006; Moreau et al. 2003; Uren et al. 2007).
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1.6 - B-cell lymphoma extra-long (Bcl-xl)
Bcl-xl is a 233 amino acid protein, consisting of seven alpha-helices (Boise et al.
1993; Muchmore et al 1997). Like the other anti-apoptotic proteins, Bcl-xl contains
multiple BH domains. Specifically, Bcl-xl contains a BH1, a BH2, a BH3, and a BH4
domain. In the normal configuration of the protein, the first three BH domains are in
close proximity and appear to form a hydrophobic binding pocket (Muchmore et al
1997). All three of these BH domains seem to be essential for the anti-apoptotic function
of Bcl-xl, as mutation or deletion of any one of them abrogates its anti-apoptotic activity
(Muchmore et al 1997). The BH3 domain is the most common site for the interaction of
Bcl-2 family members; the proximity of the other BH domains in the hydrophobic
binding pocket likely enhances the ability of other Bcl-2 family members to bind to this
region. The BH3 domain of Bcl-xl has been shown to interact with both multi-domain
and BH3-only pro-apoptotic proteins (Kazi et al. 2011; Kelekar & Thompson 1998;
Muchmore et al 1997).
Under normal conditions, Bcl-xl is found in both the cytosol and the
mitochondrial outer membrane (Hsu et al.1997; Wolter et al. 1997). Free cytosolic Bclxl appears to exist mainly in homodimers. These dimers are formed by one Bcl-xl
protein inserting its hydrophobic c-terminus into the pocket formed by the BH domains
of another Bcl-xl protein (Jeong et al 2004). This sequesters the c-terminal membranelocalization domain and allows the protein to remain cytosolic, while also blocking the
BH3 domain. However, the bonds of the Bcl-xl homodimers are easily broken when the
anti-apoptotic activity of Bcl-xl is required. Expression of a BH3-only protein, such as
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Bad, has been shown to break apart the Bcl-xl homodimers and allow Bcl-xl to
translocate to the mitochondrial outer membrane (Jeong et al 2004). When Bcl-xl inserts
its c-terminal membrane domain into the mitochondrial outer membrane, the hydrophobic
binding pocket is free to bind to other Bcl-2 family members (Jeong et al 2004). In fact,
the c-terminus of Bcl-xl appears to be necessary to bind to and sequester the proapoptotic multi-BH domain protein Bax (Jeong et al 2004).
Bcl-xl has been shown to be of particular importance in neuronal apoptosis (Boise
et al. 1993; Frankowski et al. 1995; Motoyama et al. 1995; Rubin et al. 1994) and is
considered by some to be the most effective anti-apoptotic protein (Ming et al. 2006).
Part of the reason for its efficacy and crucial role in apoptosis may be its ability to
specifically target the mitochondrial outer membrane, a crucial site for the regulation of
apoptotic events. Unlike the other anti-apoptotic Bcl-2 family members, Bcl-xl contains
a membrane localization sequence specific to the mitochondrial outer membrane
(Kaufmann et al. 2003; Lindsay et al. 2011). Bcl-xl contains a classic c-terminal
membrane targeting sequence flanked by groups of basic amino acids (Kaufmann et al.
2003; Lindsay et al. 2011). This sequence allows Bcl-xl to localize specifically to the
mitochondrial membrane, while Bcl-2, which contains a similar membrane localization
sequence without the flanking groups of basic amino acids, does not specifically target
mitochondria (Kaufmann et al. 2003; Lindsay et al. 2011). Because of its overall
importance and its specific importance in neuronal cells, we will focus on Bcl-xl as our
main anti-apoptotic protein of interest.
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1.7 – Rationale
Neuronal apoptosis plays a crucial role in normal development and in a number of
diseases. In normal development, the Bcl-2 family of proteins are important regulators of
neuronal apoptosis, and alteration of these proteins can result in significant abnormalities
(Lindsten et al. 2000; Motoyama et al. 1995; Shindler et al. 1997). Bcl-2 family
members have also been shown to play a key role in the regulation of neuronal apoptosis
in both chronic conditions, such as Alzheimer's disease (Higgins et al. 2010) and
Parkinson's disease (Vila & Przedborski, 2003), and in acute trauma, such as ischemia
(Niizuma et al. 2009; Steckley et al. 2007) and spinal cord injury (Kotipatruni et al.
2011).
We have previously shown that the BH3-only Bcl-2 family member, Puma, plays
an important role in the mediation of neuronal apoptosis due to a number of cell stressors
(Ambacher et al. 2012; Galehdar et al. 2010; Steckley et al. 2007). The BH3 domain has
been shown to be the site of Puma's interactions with both multi-domain (e.g. Bax) and
anti-apoptotic (e.g. Bcl-xl) members of the Bcl-2 family (Cartron et al. 2004; Day et al.
2008; Du et al. 2011; Gautier et al. 2011; Nakano & Vousden 2001; Steckley et al. 2007;
Yu et al. 2001 Gallenne et al. 2009; Yee & Vousden 2008; Zhang et al. 2009). Both Bax
and Bcl-xl have been shown to localize at the mitochondria when the cell is undergoing
apoptosis (Carton et al. 2003; Gardia et al. 2004; Goping et al. 1998; Kaufmann et al.
2003; Lalier et al. 2007; Lindsay et al. 2011; Nechustan et al. 1999).

We and others

have found that Puma also localizes to the mitochondria during apoptosis, but the precise
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mechanism of this membrane targeting and whether it is important for apoptotic function
of the protein remain unclear. However, our preliminary studies indicate that the cterminus of Puma contains a motif that may be involved in targeting the protein to the
mitochondrial membrane. In this work, we will attempt to identify the region of Puma
responsible for its mitochondrial-localization. We will also examine the importance of
this region and the BH3 domain of Puma in its interactions with other Bcl-2 family
members and its apoptotic activity.

1.8 - Hypothesis and Objectives
We hypothesize that both the BH3 domain and a distinct mitochondrial
localization region of p53-upregulated mediator of apoptosis (Puma) are required for
Puma-mediated neuronal apoptosis.
Objectives:
1. To determine whether BH3 domain mediated BCL-2 family interactions
are required for mitochondrial localization of Puma
2. To determine whether the c-terminus is required for mitochondrial
targeting of Puma
3. To determine whether the c-terminus is required for Puma-induced
neuronal apoptosis
4. To determine whether the c-terminus is required for Puma interaction with
Bcl-xl and/or Bax
5. To determine whether the c-terminus is required for co-localization of
Puma and Bcl-xl
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Chapter 2 – Materials and Methods
2.1 – Cell Culture
Neuro-2A (N2A) cells are an adherent neuronal cell line, derived from a
neuroblastoma in a strain A albino mouse (Augusti-Tocco & Sato 1969; Klebe & Ruddle
1969). Differentiation of the cell line into a more neuronal cell-type via serumwithdrawal has been well-documented (Amano et al. 1972; Evangelopoulos et al. 2005).
Upon differentiation, cells develop extensive neurites and produce levels of caspase-3
comparable to primary neurons (Amano et al. 1972; Evangelopoulos et al. 2005). Early
studies demonstrated that N2A cells express choline acetyltransferase and tyrosine
hydroxylase, enzymes required for neurotransmitter synthesis (Amano et al. 1972;
Augusti-Tocco & Sato 1969). They have also been shown to contain glutamate (NMDA)
receptors (LePage et al. 2005; Van der Valk JB & Vijverberg 1990) and voltage-gated
sodium channels (LePage et al. 2005). In cell-death studies, these cells have been shown
to behave in a similar manner to primary neurons (Klebe et al. 1969; Gotoh et al. 2012).
Because these cells are easy to transfect and exhibit neuronal behaviour, we chose
differentiated N2As as our preferred cell-type for these experiments.
Neuro-2A (N2A) cells (ATCC #CCL131) were cultured in complete media
(Minimum Essential Medium (MEM) (Invitrogen #11095), 10% Fetal Bovine Serum
(FBS) (Invitrogen #10437-028), 10 μg/ml gentamycin (Invitrogen #15710), and 1%
penicillin/streptomycin (Invitrogen #15070063)) at 37⁰C in 5% CO2. To plate, cells were
washed once with 0.25% Trypsin-EDTA (Invitrogen #25200) and then incubated with
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0.25% Trypsin-EDTA (Invitrogen #25200) at 37⁰C in 5% CO2 (humidified incubator) for
five minutes. Cells were then suspended in complete media at an appropriate density for
plating. For live-cell microscopy experiments, cells were plated at a density of 15000
cells per glass-bottomed 35mm dish. For fixed-cell microscopy experiments, cells were
plated at 5000 cells per well on glass cover slips (Fisher Scientific #12-545-83) in 4-well
dishes. For co-immunoprecipitation (co-IP) experiments, cells were plated at a density of
45000 cells per 60mm dish. The day after plating, cells for all experiments were
differentiated by serum-withdrawal (Amano et al. 1972; Evangelopoulos et al. 2005). In
summary, cells were washed once in 1x PBS then incubated in serum-free media
(Minimum Essential Medium (MEM) (Invitrogen #11095)) at 37⁰C in 5% CO2
(humidified incubator) for 24 hours to induce differentiation. Cells were then maintained
in complete media for the duration of treatment.

2.2 – Plasmid constructs
HA-Puma and HA-Puma (ΔBH3) cloned in pCEP4 vector were generously
donated by Dr. Vogelstein (Yu et al. 2001). The plasmids and the desired vector, GFP
C1 (Clontech #6084-1), were digested with Kpn I (New England Biolabs #R0142L) and
BamH 1 (New England Biolabs #R0136L) restriction enzymes (Table 1). The digested
DNA was then ligated into the digested GFP C1 vector with T4 DNA Ligase (New
England Biolabs #M0202S) (Table 2) at 4ºC overnight.
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The other GFP-Puma plasmids, GFP-Puma (1-160) and GFP-Puma (151-93) were
generated by PCR amplification (Table 3) and cloned into GFP C2 vector between Eco
RI and Sal I. The DNA template for Puma was diluted to 10ng/μl and and a PCR was run
using Qiagen Taq (Qiagen #201203) and High Fidelity Taq (Qiagen #202602) (Table 3).
Ten μl of the PCR product was then run on a 1.5% agarose gel and purified with the
Qiagen Gel Purification kit as per manufacturer's instructions (Qiagen #28704). The
purified product and 5μg of the GFP C2 vector were then digested with Eco RI (New
England Biolabs #R0101L) and Sal I (New England Biolabs #R0138L) restriction
enzymes (Table 1). The digested vector and DNA were then ligated with T4 DNA
Ligase (New England Biolabs #M0202S) (Table 2) overnight at 4ºC. All plasmids are
based on the Puma-α isoform and were confirmed by sequencing.
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Figure 4 - GFP-Puma plasmids. A summary of the sequence of the various GFP-Puma
plasmids. GFP-Puma (WT) consists of a GFP tag and the full Puma sequence; GFPPuma (ΔBH3) consists of a GFP tag and the Puma sequence with the BH3-domain
deleted; GFP-Puma (1-160) consists of a GFP tag and the Puma sequence without the cterminus; and GFP-Puma (151-193) consists of a GFP tag and the Puma c-terminus only.
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2.3 - Transfection
Differentiated N2As were transfected using calcium/phosphate. For live-cell
confocal microscopy, cells in 35mm glass-bottomed dishes were transfected using 1ug of
plasmid DNA (GFP, GFP-Puma (WT), GFP-Puma (∆BH3), GFP-Puma (1-160), or GFPPuma (151-193)) per dish. Plasmid DNA was diluted in 45µl ddH20 and then mixed
with 5µl of 2.5M CaCl2. Fifty microlitres of 2xHBS (0.28M NaCl, 0.05M HEPES,
1.5mM Na2HPO4, at pH 7.1) was added drop-wise and the resulting mixture was
carefully inverted two to three times. To each 35mm dish, 100µl of this solution was
added drop-wise.
For fixed-cell confocal microscopy and live-cell microscopy, cells in 4-well
dishes were transfected using 0.25ug of plasmid DNA (GFP, GFP-Puma (WT), GFPPuma (∆BH3), GFP-Puma (1-160), GFP-Puma (151-193) and/or 3x Flag-Bcl-xl) per
well. One microgram of plasmid DNA was diluted in 60ul of ddH20 and then mixed
with 6.7ul of 2.5M CaCl2. To this solution, 66.7ul of 2xHBS (0.28M NaCl, 0.05M
HEPES, and 1.5mM Na2HPO4, at pH 7.1) was added drop-wise and the resulting
mixture was carefully inverted two to three times. Thirty-three microlitres of this
solution was added drop-wise to each well in a 4-well plate.
For co-immunoprecipitation experiments, cells in 60mm dishes were transfected
using 3ug of plasmid DNA (GFP, GFP-Puma (WT), GFP-Puma (∆BH3), GFP-Puma (1160), GFP-Puma (151-193), 3x Flag-Bcl-xl, and/or 3xFlag) per dish. Three micrograms
of plasmid DNA was diluted in 300µl distilled water and then mixed with 33.5ul of 2.5M

38
CaCl2. To this solution, 334ul of 2xHBS (0.28M NaCl, 0.05M HEPES, 1.5mM
Na2HPO4, at pH 7.1) was added drop-wise and the resulting mixture was carefully
inverted two to three times. The entirety of this solution was added drop-wise to each
60mm dish.

2.5 - Peptide treatment
For experiments with GFP or GFP-Puma (WT) transfected cells, cells were
treated with 1μM of either Bax-Hα1 (CanPeptide #CP08640) or Bax-Hα1(D33A)
(CanPeptide #CP08641) Tat-fused peptide per well 12 hours after transfection. Tat is a
short sequence of basic amino acids derived from human immunodeficiency virus that
allows the transport of proteins across cell membranes (Fawell et al. 1994; Ruben et al.
1989; Vives et al. 1997). See Table 5 for complete peptide sequences. Peptide treatment
was repeated every six hours thereafter, for a total of 28 hours post-transfection, at a
concentration of 0.2μM of either Bax-Hα1 or Bax-Hα1(D33A) tat-peptide per well.

2.6 – Cell death assesment by Hoechst 33342 and Propidium Iodide staining
Hoechst 33342 (Sigma #B2261) was added to cells at a final concentration of
1μg/ml and samples were incubated for 20 minutes at 37⁰C in 5% CO2 (humidified
incubator). For staining with Propidium Iodide, Propidium Iodide (Sigma # P1470) was
added to cells at a final concentration of 1μg/ml and samples were incubated for 20
minutes at 37⁰C in 5% CO2 (humidified incubator).
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To examine apoptosis and cell death after transfection with GFP-Puma plasmids,
cells were stained with Hoechst 33342 and/or Propidium Iodide at 28 hours posttransfection or 36 hours after the initial drug treatment. Nuclear morphology was
visualized with a 40x objective lens under ultra-violet (UV) light (for Hoechst 3342)
and/or with a rhodamine (TRITC) filter (for Propidium Iodide) using a Zeiss Axiovert
200 fluorescent microscope. At least five representative images per well were captured
using Zeiss Axiovision 4.8 software and at least 500 nuclei were counted for each
treatment. For analysis of apoptosis by Hoechst staining, nuclei were categorized as
either healthy or apoptotic (blebbed, shrunken, and/or fragmented) as previously
described (Steckley et al. 2007). For each treatment, the percentage of apoptotic cells
was calculated as the number of GFP-positive apoptotic cells out of the total number of
cells. For analysis of cell death by Propidium Iodide and Hoechst staining, Hoechststained nuclei were categorized as either live (Propidium Iodide-negative) or dead
(Propidium Iodide-positive). Percent cell death was calculated as the number of
Propidium Iodide-positive (dead cells) out of the total number of cells for each treatment.

2.7 - Mitotracker ® Red CMXRos staining
Neuro2A cells were transfected with GFP, GFP-Puma (WT), GFP-Puma (∆BH3),
GFP-Puma (1-160), or GFP-Puma (151-193) plasmids (see Transfection). Twenty-four
hours post-transfection, cells were stained with Mitotracker ® Red CMXRos (Invitrogen
#M-7512). at 1ug/ml in complete MEM culture media to identify mitochondria and
counterstained with Hoechst 33342 to visualize cell nuclei. Hoechst 33342 and
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Mitotracker ® Red CMXRos were added to the cells simultaneously and samples were
incubated for 20 minutes at 37⁰C in 5% CO2 (humidified incubator). Samples were
visualized with a 63x objective lens on an LSM 510 Meta Zeiss confocal microscope and
images were captured using Zeiss software. To detect Hoechst 33342 staining, an
excitation wavelength of 405nm at 3% intensity was used with a bandpass filter for 420480nm. For GFP, the fluorophore was excited at 3% intensity at 488nm with a bandpass
filter for 505-530nm. Mitotracker ® Red CMXRos fluorescence was excited at a
wavelength of 633nm at 10% intensity and viewed through a 650nm longpass filter.

2.8 - Immunofluorescence
Cells were incubated at 37⁰C in 5% CO2 (humidified incubator) for 20 minutes
with Hoechst 33342 (Sigma #B2261) diluted to 1ug/ml in complete media. Cells were
then fixed with Lana’s fixative (4% paraformaldehyde (Sigma-#P6148), 160mM dibasic
and monobasic sodium phosphate, and 0.2% picric acid (Sigma-#80456)) for 20 minutes
at room temperature, then washed twice with 1xPBS. Cells were incubated at room
temperature for 20 minutes with permeabilizing solution (0.2% Triton-X in 1xPBS), and
then in blocking solution (0.2% Triton-X and 2% BSA in 1x PBS) for 45 minutes at room
temperature. Cells were then incubated overnight at 4⁰C with primary antibody at a
1:500 dilution in blocking solution (1x PBS, 0.2% Triton-X, 2% BSA). Primary
antibodies used for immunofluorescent staining were Anti-Tomm-20 (Abcam #ab56783),
or Anti-Flag M2 (Sigma #F-3165). The following day, cells were washed twice in 1x
PBS and incubated at room temperature for one hour with fluorescent secondary antibody
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at a 1:500 dilution. Secondary antibody used in this experiment was Alexa Fluor® 594
goat anti-mouse IgG (Invitrogen #A11005). Cells were washed twice in 1x PBS and then
the glass coverslips were affixed to slides using Immu-mount (Thermo Scientific
#9990402). Samples were visualized with a 63x objective lens on an LSM 510 Meta
Zeiss confocal microscope and images were captured using Zeiss software. To detect
Hoechst 33342 staining, an excitation wavelength of 405nm at 3% intensity was used
with a bandpass filter for 420-480nm. For GFP, the fluorophore was excited at 3%
intensity at 488nm with a bandpass filter for 505-530nm. Alexa Fluor® 594
fluorescence was excited at a wavelength of 543nm at 10% intensity and viewed through
a 585nm longpass filter.

2.9 – Co-immunoprecipitation
Anti-Flag M2 agarose beads (Sigma #A2220) were aliquoted into a 15ml falcon
tube and washed with 1xPBS, then centrifuged at 500xg for five minutes. The PBS was
then carefully aspirated off and the rinse was repeated twice. Flag-bead/CHAPS slurry
was prepared by re-suspending the rinsed Flag-beads in an equal volume of 1% CHAPS
buffer (10mM HEPES, 150mM NaCl, 0.5mM EDTA, 1% CHAPS (Sigma #C9426),
0.5mM phenylmethyl sulfonyl fluoride (PMSF) (Bioshop #PMS123), 10mg/ml
Aprotonin, 2mg/ml Leupeptin).
Twenty-four hours after transfection, cells were rinsed twice with ice-cold 1x PBS
and then lysed with 300ul of 1% CHAPS on ice for 30 minutes. The resulting lysate was
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centrifuged at 14000xg for 12 minutes at 4⁰C to pellet cell debris. Protein concentration
in the supernatant was determined using the Pierce © BCA protein determination assay
(Thermo Fisher Scientific © #22325). Five hundred micrograms of protein from each
sample was added to 50µl of the Flag-bead/CHAPS slurry and rotated at 4⁰C for one
hour. Twenty-five micrograms of protein from each sample was not exposed to beads
and reserved for Western blotting to assess protein expression.
After incubation, beads were rinsed three times with 1x PBS, centrifuged at
14000xg for 20 seconds and aspirated with a syringe. Beads were resuspended in 50µl
1% CHAPS and 10µl of 6x sodium dodecyl sulfate (SDS) (Bioshop #SDS101). The
resulting mixture was boiled at 100⁰C for 10 minutes to denature the protein and release it
from the beads. Twenty-five microlitres of each of the bead-incubated samples and the
entirety of the 25µg lysate samples were analysed by Western blot (see Western Blot).

2.10 - Western Blot
Protein samples were run on a 12.5% polyacrylamide gel and transferred to a
nitrocellulose membrane by semi-dry electroblotting. The membrane was washed three
times in 1x TBS-T (150mM NaCl, 10mM Tris, 0.05% Tween-20 (Fisher Biotech
#BP1605)) and blocked for an hour in blocking buffer (10% milk (w/v) in 1x TBS-T) at
room temperature on a rocker. The membrane was again washed three times in 1x TBST, and then incubated overnight at 4⁰C with primary antibody at 1:10,000 dilution in
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blocking buffer (5% milk (w/v) in 1x TBS-T). Primary antibody used in this experiment
was anti-GFP (Invitrogen #A6455).
The following morning, membranes were washed three times in 1x TBS-T and
incubated with secondary antibody at 1:10,000 dilution in blocking buffer (5% milk (w/v)
in 1x TBS-T) for one hour at room temperature on a rocker. The secondary antibody
used for this experiment was a horseradish peroxidase (HRP)-conjugated goat anti-rabbit
IgG (Biorad #170-6515). The membrane was once again washed three times in 1x TBST, and then Pierce ECL Western Blotting Substrate (Thermo Scientific #32106) was used
to detect immunoblotted proteins by chemiluminescence. The membrane was exposed to
Kodak Biomax maximum sensitivity film (Kodak #8294985) to capture an image of the
immunoblotted proteins.

2.11 - Data Analysis
Data were reported as mean and standard deviation. The value n represents
experiments conducted using independent passages of Neuro-2A cells. Differences
between groups were calculated using one-way ANOVA followed by Dunnet's post hoc
test. Data were considered statistically significant when p < 0.01. Statistical analyses
were conducted with GraphPad Prism software version 5.0 (GraphPad software, San
Diego, CA).
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Chapter 3 - Results
3.1 – Interaction with other BCL-2 family proteins is required for Puma's apoptotic
activity but not its localization.
We first sought to determine whether Puma localization to the mitochondria was
mediated through interactions with other Bcl-2 family proteins. The BH3 domain of
Puma is known to be required for its interaction with other Bcl-2 family proteins (Chen
et al. 2005; Day et al. 2008; Gautier et al. 2011; Kuwana 2005). It has previously been
demonstrated that the first α helix (Hα1) of Bax can interact with the BH3 domain of
Puma, but not other Bcl-2 family proteins (Cartron et al. 2004; Lalier et al. 2007).
Furthermore, it was shown that a peptide mimicking the Bax-Hα1 region could inhibit the
interaction of Puma with the Bcl-2 protein, Bax, in vitro, and that an aspartate to alanine
mutation at amino acid residue 33 of this peptide abrogates its binding to the Puma-BH3
domain (Cartron et al. 2004; Lalier et al. 2007). To determine whether Puma's
interactions with other Bcl-2 family proteins are required for its localization and
apoptotic activity we synthesized Tat-fused Bax-Hα1 and Bax-Hα1(D33A) peptides to
facilitate their uptake into neurons. Differentiated Neuro2A cells were transfected with
either GFP-Puma or GFP and after 12 hours cells were treated with 1μM of either TatBax-Hα1 or Tat-Bax-Hα1(D33A) peptide. The tat-peptide treatment was repeated every
six hours at a concentration of 0.2μM to compensate for potential degradation. Twentyeight hours following transfection, nuclei were Hoechst 33342 stained to identify
apoptotic cells.
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We found that N2A cells expressing GFP-Puma exhibited a marked increase in
the fraction of apoptotic cells as compared to cells expressing GFP alone (Figure 5).
Furthermore, we found that cells transfected with GFP-Puma and treated with the TatHα1 peptide exhibited significantly less apoptosis than those treated with Tat-BaxHα1(D33A) peptide or no peptide (Figure 5). We observed that N2A cells expressing
GFP-Puma exhibited a punctate, cytoplasmic GFP staining pattern. Interestingly, this
staining pattern was not affected by treatment of cells with the Tat-Bax-Hα1 peptide
(Figure 5). Taken together these results suggest that while interaction of Puma with Bcl2 family proteins is required for its apoptotic activity these interactions are not required
for its characteristic localization.
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Figure 5 - Hα1 tat-peptide interferes with Puma-induced apoptosis but not its
localization. Differentiated Neuro2A cells were transfected with GFP-Puma (WT) or
GFP. Cells transfected with GFP-Puma were treated with Bax-Hα1 or Bax-Hα1(D33A)
tat-peptide beginning with 1μM at 12 hours post-transfection followed by 0.2μM every
six hours thereafter. At 28 hours post-transfection, cells were stained with Hoecsht
33342 and viewed by fluorescence microscopy to assess nuclear morphology. (a) Cells
that displayed characteristics of apoptosis (nuclear condensation and blebbing) were
counted as apoptotic. Apoptotic Cells (%) was calculated as GFP-positive apoptotic
cells out of total GFP-positive cells (*p<0.01, n=4). Data were analyzed using one-way
ANOVA and Dunnet's Multiple Comparison test. (b) (i) Cells transfected with GFPPuma. (ii) Cells transfected with GFP-Puma and treated with Bax-Hα1(D33A) tatpeptide. (iii) Cells transfected with GFP-Puma and treated with Bax-Hα1 tat-peptide.
(iv) Cells transfected with GFP. Representative images from four independent
experiments are shown (n=4). Scale bar = 20μm.
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3.2 - Identification of a potential membrane targeting sequence in the Puma protein.
Having determined that interactions between the BH3 domain of Puma and Bcl-2
family proteins are not required its characteristic localization, we analyzed the Puma
protein sequence for potential membrane targeting motifs using MEta Server for protein
Sequence Analysis (MESSA) software. MESSA is a meta-server designed to identify
local sequence properties, three-dimensional structure, and overall function(s) of proteins
using a consensus from multiple existing computer programs (Cong & Grishin 2012).
By examining the results from the MESSA analysis, we identified two regions of
interest in the Puma protein: the well-established BH3 domain (amino acids 137-150),
and a putative localization sequence at the c-terminus of the protein (approximately
amino acids 165-185) (Figure 6). The BH3 domain is well-conserved, amphipathic, and
alpha-helical in structure (Figure 6). Although MESSA did not identify a classic
membrane-localization sequence in the Puma protein, we did identify sequence features
that suggest an important region at the c-terminus of Puma (Figure 6). The putative
localization region is well conserved and alpha-helical in structure (Figure 6). It is a
hydrophobic region flanked by basic amino acids, a sequence which resembles the
mitochondrial-localization sequence of Bcl-xl (Figure 6; Kaufmann et al. 2003).
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Residue Number Marker

--------10--------20--------30--------40--------50

Protein Sequence

MARARQEGSSPEPVEGLARDGPRPFPLGRLVPSAVSCGLCEPGLAAAPAA

Secondary Structure

cccHHccccccccHHHHHcccccccccHHcccHccccccccccccccccc

Positional Conservation

MARARQEGSSPEPVEGLARDGPRPFPLGRLVPSAVSCGLCEPGLAAAPAA

Residue Number Marker
Protein Sequence
Secondary Structure
Positional Conservation

--------60--------70--------80--------90-------100
PTLLPAAYLCAPTAPPAVTAALGGSRWPGGPRSRPRGPRPDGPQPSLSLA
ccccccccccccccccHHcccccccccccccccccccccccccccccccc
PTLLPAAYLCAPTAPPAVTAALGGSRWPGGPRSRPRGPRPDGPQPSLSLA

Residue Number Marker
Protein Sequence
Secondary Structure

-------110-------120-------130-------140-------150
EQHLESPVPSAPGALAGGPTQAAPGVRGEEEQWAREIGAQLRRMADDLNA
cHHccccccccccccccccccccccccccHHHHHHHHHHHHHHHHHHHHH

Positional Conservation

EQHLESPVPSAPGALAGGPTQAAPGVRGEEEQWAREIGAQLRRMADDLNA

Residue Number Marker
Protein Sequence
Secondary Structure
Positional Conservation

-------160-------170-------180-------190--QYERRRQEEQQRHRPSPWRVLYNLIMGLLPLPRGHRAPEMEPN
HHHHHHHHHHHHccccHHHHHHHHHHHHccccccccccccccc
QYERRRQEEQQRHRPSPWRVLYNLIMGLLPLPRGHRAPEMEPN

Protein Sequence: The input protein sequence shown in this line is highlighted
according to amino acid property: positively charged residues in blue (light blue for
partially positive), negatively charged residues in red (pink for partially negative),
hydrophobic residues in yellow and no highlight for small residues.
Secondary Structure (Consensus): The 3-state secondary structure of the query is
predicted, alpha-helix (including 3-turn and 5-turn helix), beta-strand and coils
(including any secondary structure other than helix and strand). In the result, "H"
represents alpha-helix; "E" stands for beta-strand; and "c" refers to coils.
Positional Conservation: Multiple Sequence Alignment of confident BLAST hits,
filtered by less than 90% identity and more than 40% coverage, are used to calculate the
positional conservation indices of residues in the sequence. The conserved residues
usually plays important in maintaining the function or structure of a protein. Here the
residues are highlighted from white, through yellow to dark red as the conservation level
increases.
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Figure 6 - Regions of interest in the Puma protein. MEta Server for protein Sequence
Analysis (MESSA) analysis of Puma protein (Cong & Grishin 2012). The important
regions of interest are the BH3 domain, amino acids 137-150, and the putative c-terminal
localization sequence. Here we can see that the BH3 domain falls in a highly conserved
region, appears to be amphipathic, and alpha-helical in structure. There is also a region
of interest in the c-terminus of the protein, appromixately amino acids 165-185. This
region is highly conserved and appears to contain an alpha-helical structure. It is
hydrophobic, which would aid in membrane localization and insertion, and is flanked by
basic amino acids. This resembles the localization sequence on Bcl-xl put forward by
Kaufmann et al. that is purported to localize the protein specifically to the mitochondrial
membrane (2003). Although it is not identified as a classic membrane localization
sequence, this region may be similarly responsible for the localization of Puma.
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3.3 - Analysis of protein expression confirms that GFP plasmids express proteins at
equal levels and expected molecular weights.
In order to examine the roles of the BH3 domain and the putative c-terminal
localization sequence of Puma, a number of GFP-tagged mutant plasmids were created:
GFP-Puma (WT), the GFP tag followed by full length Puma; GFP-Puma (ΔBH3), the
GFP tag followed by a variant of Puma with the BH3 domain deleted; GFP-Puma (1160), the GFP tag followed by a truncated variant of Puma containing only the first 160
amino acids; and GFP-Puma (151-193), the GFP tag followed by a truncated variant of
Puma containing only the last 42 amino acids. In order to ensure proper and equal
expression of these Puma variants, differentiated Neuro2A cells were transfected with
equal amounts of the plasmids, and protein samples were collected for analysis by
Western blot. GFP primary antibody was used to evaluate protein expression levels
because there is no single Puma antibody capable of detecting all of the different Puma
variants. Calnexin was used to ensure equal loading of the protein samples.
The GFP-Puma (WT) protein should be approximately 49 kDa (22 kDa from
Puma plus 27 kDa from the GFP tag). GFP-Puma (ΔBH3) should be about 46 kDa and
GFP-Puma (1-160) should be approximately 44 kDa. GFP-Puma (151-193) should be
about 28kDa, only a little more than GFP alone. All plasmids express protein at similar
levels and at the expected molecular weights (Figure 7).
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Figure 7 - Expression of GFP-Puma plasmids. Differentiated Neuro2A cells were
transfected with equal amounts (1μg) of the various GFP plasmids. Twenty-four hours
after transfection, protein samples were collected and expression of Calnexin and the
GFP tagged proteins was analyzed by western blot. Representative image of four
independent experiments is shown (n=4).
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3.4 – An element of the Puma c-terminus is required and sufficient for cellular
localization of Puma.
Next, we wanted to examine potential roles of the BH3-domain and the cterminus in regulating the cellular localization of Puma. In order to do so, differentiated
Neuro2A cells were transfected with GFP or one of the various GFP-Puma mutants.
Twenty-four hours after transfection, cells were stained with Hoechst 33342 as a nuclear
marker and visualized by fluorescence microscopy. Cells were counted in two
categories: those that displayed punctate, cytoplasmic GFP fluorescence and those that
displayed diffuse GFP fluorescence.
As expected, the vast majority of cells expressing GFP alone exhibited a diffuse
GFP fluorescence throughout the nucleus and cytoplasm (Figure 8). In contrast, N2A
cells expressing GFP-Puma (WT) displayed mainly punctate, cytoplasmic GFP
fluorescence (Figure 8). Cells expressing GFP-Puma (ΔBH3) and GFP-Puma (151-193),
the plasmids with intact c-termini but lacking the BH3 domain of Puma, displayed
punctate, cytoplasmic GFP fluorescence similar to the cells expressing wild-type GFPPuma (Figure 8). However, cells expressing GFP-Puma (1-160), the plasmid with an
intact BH3 domain but lacking the c-terminus of Puma, did not display punctate GFP
fluorescence and instead showed diffuse GFP fluorescence similar to cells expressing
GFP (Figure 8). This suggests that an element in the c-terminus is required and
sufficient for the cellular localization of Puma. Furthermore, it suggests that the BH3
domain is not required for cellular localization.
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Figure 8 - Puma c-terminus is required and sufficient for cellular localization.
Differentiated Neuro2A cells were transfected with GFP-Puma (WT), GFP-Puma
(ΔBH3), GFP-Puma (1-160), GFP-Puma (151-193), or GFP. Twenty-four hours posttransfection, cells were stained with Hoechst 33342 as a nuclear marker and the pattern
of GFP fluorescence was examined. Punctate Cells (%) was calculated as the number of
cells with GFP-puncti out of total number of GFP-positive cells (n=3).
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3.5 – Puma c-terminus is required and sufficient for mitochondrial-localization.
The next step was to determine the roles of the BH3 domain and c-terminus of
Puma in its ability to localize to the mitochondria. In order to do so we examined the colocalization of the various GFP-Puma proteins with Mitotracker ® Red CMXRos using
confocal microscopy. Mitotracker ® Red CMXRos is a fluorescent compound that stains
mitochondria in live cells.
Differentiated Neuro2A cells were transfected with the various GFP-Puma
plasmids. Twenty-four hours post-transfection, mitochondria were stained with
Mitotracker ® Red CMXRos and co-localization of the GFP and Mitotracker ® Red
CMXRos fluorescence was examined by confocal microscopy.
In cells transfected with GFP-Puma (WT), the majority of the characteristic GFPPuma puncti appear to co-localize with mitochondria (Figure 9, panel (b)). The GFPPuma variants with intact c-termini but without BH3 domains, GFP-Puma (ΔBH3) and
GFP-Puma (151-193), also appear to mostly co-localize with mitochondria (Figure 9,
panels (c) and (e)). However, the GFP-Puma protein with an intact BH3 domain but
lacking the c-terminus, GFP-Puma (1-160), does not appear to co-localize with
mitochondria (Figure 9, panel (d)).
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Figure 9 - Co-localization of different GFP-Puma proteins with Mitotracker ® Red
CMXRos. Differentiated Neuro2A cells were transfected with GFP-Puma (WT), GFPPuma (ΔBH3), GFP-Puma (1-160), GFP-Puma (151-193), or GFP. 24 hours posttransfection, cells were stained with Hoechst 33342 and Mitotracker ® Red CMXRos.
Co-localization of GFP-Puma proteins with mitochondria was assessed by confocal
microscopy. Blue = Hoechst 33342; Green = GFP proteins; Red = Mitotracker ® Red
CMXRos. (a) GFP appears diffuse and does not appear to co-localize with the
mitochondria. (b) GFP-Puma (WT) appears punctate and appears to co-localize with the
mitochondria. (c) GFP-Puma (ΔBH3) appears punctate and appears to co-localize with
the mitochondria. (d) GFP-Puma (1-160) appears diffuse and does not appear to colocalize with the mitochondria. (e) GFP-Puma (151-193) appears punctate and appears
to co-localize with the mitochondria. Representative images from three independent
(c)
experiments are shown (n=3). Scale Bar = 10μm.
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Although the majority of the GFP puncti in cells transfected with GFP-Puma
(WT), GFP-Puma (ΔBH3), and GFP-Puma (151-193) co-localize with mitochondria
labeled by Mitotracker ® Red CMXRos (Invitrogen #M-7512), there are some GFP
puncti remaining that are not accompanied by Mitotracker ® Red CMXRos stain. One
possible explanation for this is that Mitotracker ® Red CMXRos stains live cell
mitochondria and we are investigating cell death processes. It is possible that those GFPPuma puncti are co-localized with mitochondria that have lost their mitochondrial
membrane potential and therefore do not retain the Mitotracker ® Red CMXRos. In
order to investigate this possibility, we examined the co-localization of the various GFPPuma proteins with a mitochondrial protein, translocase of outer mitochondrial
membrane (Tomm20). Tomm20 is a mitochondrial import receptor protein that is
located on the mitochondrial membrane and can therefore be used to identify
mitochondria.
Differentiated Neuro2A cells were transfected with GFP-Puma (WT), GFP-Puma
(ΔBH3), GFP-Puma (1-160), GFP-Puma (151-193), or GFP. Twenty-four hours posttransfection, mitochondria were immunostained for Tomm20 and co-localization of GFPPuma and Tomm20 was assessed by confocal microscopy.
We found that GFP-Puma (WT) co-localized with the mitochondria stained for
Tomm20 (Figure 10, panel (b)). Similarly, GFP-Puma (ΔBH3) and GFP-Puma (151193), the Puma variants in which the C-terminal domain remains intact also exhibited
marked co-localization with Tomm20 (Figure 10, panels (c) and (e)). However, GFP-
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Puma (1-160), the Puma variant that retains the BH3-domain but lacks the c-terminus,
does not co-localize with Tomm20-stained mitochondria (Figure 10, panel (d)). These
results indicate that a sequence at the c-terminus, but not the BH3 domain of Puma, is
both necessary and sufficient for the mitochondrial localization of Puma.
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Figure 10 - Co-localization of different GFP-Puma proteins with Tomm20.
Differentiated Neuro2A cells were transfected with GFP-Puma (WT), GFP-Puma
(ΔBH3), GFP-Puma (1-160), GFP-Puma (151-193), or GFP. Twenty-four hours posttransfection, cells were stained with Hoechst 33342, fixed, and immunostained for
Tomm20. Co-localization of GFP-Puma proteins with mitochondria was assessed by
confocal microscopy. Blue = Hoechst 33342; Green = GFP plasmids; Red = Tomm20.
(a) GFP appears diffuse and does not appear to co-localize with the mitochondria. (b)
GFP-Puma (WT) appears punctate and appears to co-localize with the mitochondria. (c)
GFP-Puma (ΔBH3) appears punctate and appears to co-localize with the mitochondria.
(d) GFP-Puma (1-160) appears diffuse and does not appear to co-localize with the
mitochondria. (e) GFP-Puma (151-193) appears punctate and appears to co-localize with
the mitochondria. Representative images from three independent experiments are shown
(n=3). Scale Bar = 10μm.
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3.6 – Both the BH3 domain and a distinct c-terminal domain of Puma are required
for Puma-induced apoptosis.
To examine the roles of Puma's BH3 domain and c-terminus in its ability to
induce apoptosis, differentiated Neuro2A cells were transfected with the various GFPPuma plasmids. Twenty-eight hours after transfection, cells were stained with Hoechst
33342 and visualized by fluorescence microscopy. Hoechst 33342 is a fluorescent stain
that binds to nuclear DNA and allows the examination of nuclear morphology.
Characteristics of apoptosis are chromosome condensation and nuclear blebbing; the use
of Hoeschst 33342 stain to assess nuclear morphology is a well-established method for
evaluating apoptosis. The proportion of GFP-positive cells with blebbed and/or pyknotic
nuclei out of the total number of GFP-positive cells was calculated in order to assess the
levels of apoptosis induced by expression of the various Puma proteins.
Cells expressing the wild-type Puma protein had significantly higher levels of
apoptosis (with a mean of 49% apoptotic cells) than cells expressing GFP alone (with a
mean of 6% apoptotic cells) (Figure 11). On the other hand, expression of GFP-Puma
(ΔBH3), GFP-Puma (1-160) or GFP-Puma (151-193) did not result in a significant
increase in apoptosis as compared to expression of GFP alone (Figure 11). The variants
of Puma lacking either the BH3 domain or the c-terminus were unable to induce
apoptosis. Taken together, these data suggest that both the BH3 domain and the cterminus of Puma are required for its apoptotic activity.
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Figure 11 - Differing levels of apoptosis induced by various GFP-Puma proteins.
Differentiated Neuro2A cells were transfected with GFP-Puma (WT), GFP-Puma
(ΔBH3), GFP-Puma (1-160), GFP-Puma (151-193), or GFP. Twenty-eight hours posttransfection, Hoechst 33342 was used to stain cellular nuclei. Nuclear morphology was
examined and cells that displayed characteristics of apoptosis (nuclear condensation and
blebbing) were counted as apoptotic. (a) Apoptotic Cells (%) was calculated as GFPpositive apoptotic cells out of total GFP-positive cells (*p<0.01, n=4). Data were
analyzed using one-way ANOVA and Dunnet's Multiple Comparison test. (b)
Representative images of the quantified results in panel (a) are shown. Apoptotic nuclei
are marked with (>). Scale Bar = 20μm.
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In order to ensure that the Puma variants were not inducing cell death by a
process other than apoptosis and to ensure that assessment of nuclear morphology was
sufficient to evaluate cell death, we used Propidium Iodide stain to compare the ability of
different Puma variants to induce cell death. Propidium Iodide is an intercalating agent
that binds DNA, but is excluded from viable cells by intact cellular membranes.
However, Propidium Iodide can permeate dead cells where it binds to and fluorescently
labels DNA, allowing visualization by fluorescence microscopy.
Differentiated Neuro2A cells were transfected with GFP-Puma (WT), GFP-Puma
(ΔBH3), GFP-Puma (1-160), GFP-Puma (151-193), or GFP. Twenty-eight hours after
transfection, cells were stained with Hoechst 33342 as a nuclear marker and Propidium
Iodide to identify dead cells. Cells were then visualized by fluorescent microscopy and
the proportion of Propidium Iodide-positive cells to total number of cells was calculated
in order to determine the level of cell death induced by each plasmid.
Expression of wild-type Puma resulted in an increase in cell death, with a mean of
29%, as compared to GFP alone, with a mean of 7% (Figure 12). However, expression of
GFP-Puma (ΔBH3), GFP-Puma (1-160), and GFP-Puma (151-193) did not increase cell
death as compared to expression of GFP alone (Figure 12). These results and the results
from the Hoechst stain analysis combine to show that Puma requires both its BH3 domain
and c-terminus to induce apoptosis.
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Figure 12 - Differing levels of cell death induced by various GFP-Puma proteins.
Differentiated Neuro2A cells were transfected with GFP-Puma (WT), GFP-Puma
(ΔBH3), GFP-Puma (1-160), GFP-Puma (151-193), or GFP. Twenty-eight hours posttransfection, cells were stained with Hoechst 33342 and Propidium Iodide. Cells positive
for Propidium Iodide were counted as dead. (a) Cell death (%) was calculated as
Propidium Iodide-positive cells out of the total number of cells (n=3). (b) Representative
images of the quantified results in panel (a) are shown. Examples of Propidium Iodidepositive cells are marked with (>). Scale Bar = 20μm.
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3.7 – Puma BH3 domain, but not Puma c-terminus, is required to bind to Bcl-xl in
vitro.
One of the ways that BH3-only proteins, such as Puma, are able to promote
apoptosis is through the indirect activation of Bax. In this model of Bax activation, BH3only proteins bind to anti-apoptotic proteins so that the anti-apoptotic proteins cannot
bind to and inhibit Bax. The anti-apoptotic protein Bcl-xl has been shown to play a
particularly important role in neuronal apoptosis (Motoyama et al. 1995). Bcl-xl also
appears to localize specifically to the mitochondria, which seems to be an important site
for Bcl-2 family member interactions (Kaufmann et al. 2003; Lindsay et al. 2011).
Therefore, we examined whether the c-terminal region of Puma, in addition to the BH3
domain, is required for binding to Bcl-xl.
Differentiated Neuro2A cells were co-transfected with one of the various GFPPuma plasmids and either Flag-tagged Bcl-xl or empty Flag vector. Protein was collected
from the transfected cells and was immunoprecipitated using Flag-beads. The ability of
the various Puma proteins to bind the Flag-tagged Bcl-xl was assessed by immunoblot
with GFP-antibody.
As shown in Figure 13, both GFP-Puma (WT) and GFP-Puma (1-160), which
contain the BH3 domain, immunoprecipitated with Bcl-xl. However, GFP-Puma
(ΔBH3), which retains the c-terminal region but lacks the BH3 domain, did not coimmunoprecipitate with Bcl-xl (Figure 13). We did not detect any non-specific binding
between GFP and Flag-Bcl-xl, GFP-Puma (WT) and Flag, or cell lysate and beads
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(Figure 13). These results suggest that the Puma c-terminal region is not required for
binding to Bcl-xl in vitro.

GFP-Puma (WT) + Flag
GFP + Flag-Bcl-xl
GFP-Puma (WT) + Flag-Bcl-xl

GFP-Puma (WT) + Flag
GFP + Flag-Bcl-xl
GFP-Puma (WT) + Flag-Bcl-xl
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Figure 13 - Puma BH3 domain, but not Puma c-terminus, is required to bind to Bclxl in vitro. Differentiated Neuro2A cells were transfected with GFP-Puma (WT), GFPPuma (ΔBH3), GFP-Puma (1-160), or GFP, as well as Flag-tagged Bcl-xl or Flag-tag.
24 hours post-transfection, protein was collected and immunoprecipitated with Flagbeads. An immunoblot was then performed on the samples using GFP-antibody to
identify any co-precipitated GFP-Puma proteins. Representative blot from three
independent experiments is shown (n=3).
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3.8 – Puma c-terminus is required for co-localization with Bcl-xl in N2A cells in
situ.
The co-immunoprecipitation experiments were performed in whole-cell lysate,
which makes the localization of proteins irrelevant by creating a homogeneous mixture of
the cellular components. Proteins may be able to bind in cell lysate, but might not do so
in an intact cellular environment if they localize to different areas of the cell and
therefore do not have the opportunity to interact. Perhaps the localization sequence at the
c-terminus of Puma is not required to bind to Bcl-xl in cell lysate but is required to colocalize with and bind to Bcl-xl in the intact cellular environment. In order to investigate
this possibility, we used confocal microscopy to examine the ability of the various Puma
mutants to co-localize with Flag-Bcl-xl.
Differentiated Neuro2A cells were transfected with GFP-Puma (WT), GFP-Puma
(ΔBH3), GFP-Puma (1-160), GFP-Puma (151-193), or GFP, as well as Flag-tagged Bclxl. Twenty-four hours post-transfection, cells were stained with Hoechst 33342 as a
nuclear marker and fixed. Flag-tagged Bcl-xl was immunofluorescently labeled and the
co-localization of Flag-tagged Bcl-xl and the various GFP-Puma mutants was assessed
using confocal microscopy.
As shown in Figure 14 (panel b) GFP-Puma (WT) protein exhibits marked colocalization with Flag-Bcl-xl. Similarly, GFP-Puma (ΔBH3) and GFP-Puma (151-193),
which possess the c-terminal region but lack the BH3 domain, also co-localize with
Flag-Bcl-xl (Figure 14, panels (c) and (e)). However, GFP-Puma (1-160), which retains
the BH3-domain but lacks the c-terminus, does not appear to co-localize with Flag-Bcl-xl
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(Figure 14, panel (d)). Taken together these results suggest that the c-terminus, but not
the BH3 domain, is required for Puma to co-localize with Bcl-xl in N2A cells and likely
for Puma-Bcl-xl interaction in the cellular context.
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Figure 14 - Puma c-terminus is required for co-localization with Bcl-xl in N2A cells
in situ. Differentiated Neuro2A cells were transfected with GFP-Puma (WT), GFPPuma (ΔBH3), GFP-Puma (1-160), GFP-Puma (151-193), or GFP, as well as Flag-Bclxl. Twenty-four hours post-transfection, cells were stained with Hoechst 33342, fixed,
and immunofluorescently stained for Flag-Bcl-xl. Co-localization of the various GFPPuma plasmids with Flag-Bcl-xl was assessed by confocal microscopy. Blue = Hoechst
33342; Green = GFP plasmids; Red = Flag-Bcl-xl. (a) GFP appears diffuse and does not
appear to co-localize with Flag-Bcl-xl. (b) GFP-Puma (WT) appears punctate and
appears to co-localize with Flag-Bcl-xl. (c) GFP-Puma (ΔBH3) appears punctate and
appears to co-localize with Flag-Bcl-xl. (d) GFP-Puma (1-160) appears diffuse and does
not appear to co-localize with Flag-Bcl-xl. (e) GFP-Puma (151-193) appears punctate
and appears to co-localize with Flag-Bcl-xl. Representative images from three
independent experiments are shown (n=3). Scale Bar = 10μm.
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3.9 - Puma BH3-domain, but not Puma c-terminus, is required to bind to Bax in
vitro.
We and others have previously demonstrated that, in addition to interacting with
anti-apoptotic Bcl-2 family proteins, Puma can also interact with the pro-apoptotic
member Bax in vitro (Steckley et al 2007, Cartron et al. 2004). This would suggest that
Puma may also contribute to cell death through direct activation of Bax. Therefore, we
next examined whether the Puma c-terminus was required for Puma to interact with Bax
using a co-immunoprecipitation approach.
Differentiated Neuro2A cells were transfected with one of the various GFP-Puma
mutants and Flag-tagged Bax. Twenty-four hours post-transfection, protein was collected
and immunoprecipitated with Flag-beads. Samples were then run on SDS-PAGE and
immunoblotted with GFP antibody to examine the potential of the various GFP-Puma
mutants to bind to and immunoprecipitate with Flag-Bax.
Both GFP-Puma (WT) and GFP-Puma (1-160), the proteins with intact BH3
domains, were able to bind to Flag-Bax (Figure 15). However, the Puma proteins with
intact c-termini but missing the BH3 domain (GFP-Puma (ΔBH3) and GFP-Puma (151193)) were unable to bind to Flag-Bax (Figure 15). We did not detect non-specific
binding between GFP and Flag Bax, or cell lysate and beads (Figure 15). These results
suggest that the c-terminal region is not required for Puma to interact with Bax in vitro.
However, it is possible that the c-terminal region could be required for co-localization
and interaction of Puma with Bax in intact cells similar to the situation with Bcl-xl.

GFP + Flag-Bax
GFP-Puma (WT) + Flag-Bax

GFP + Flag-Bax
GFP-Puma (WT) + Flag-Bax
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Figure 15 - Puma BH3-domain, but not Puma c-terminus, is required to bind to Bax
in vitro. Differentiated Neuro2A cells were transfected with GFP-Puma (WT), GFPPuma (ΔBH3), GFP-Puma (1-160), GFP-Puma (151-193), or GFP, as well as Flagtagged Bax. Twenty-four hours post-transfection, protein was collected and
immunoprecipitated with Flag-beads. An immunoblot was then performed on the
samples using GFP-antibody to identify any co-precipitated GFP-Puma proteins.
Representative blot from three independent experiments is shown (n=3).
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Chapter 4 - Discussion
Our lab has previously shown the importance of Puma expression and
mitochondrial-localization in neuronal apoptosis due to a variety of cell stressors,
including: endoplasmic reticulum, trophic factor withdrawal, and oxidative stress
(Ambacher et al. 2012; Galehdar et al. 2010; Steckley et al. 2007). Here, we have
identified that a motif at the c-terminus of the Puma protein, but not its BH3 domain nor
BH3 domain-mediated Bcl-2 family interactions, is responsible for its mitochondriallocalization. We have also shown that both this c-terminal mitochondrial-localization
sequence and the BH3 domain of Puma are necessary for the apoptotic activity of the
Puma protein.

4.1 - Identification of two important regions in the Puma protein
In order to explore the possibility of another region of importance in the Puma
protein, we analyzed the Puma sequence using the MEta Server for protein Sequence
Analysis (MESSA) software (Cong & Grishin 2012). Our analysis identified an
amphipathic, alpha-helical domain at amino acids 137-150 in the protein (Figure 6).
These features are consistent with the well-documented BH3 domain of Puma. Like all
BH3-only members of the Bcl-2 family, Puma contains a BH3 domain responsible for its
interactions with other Bcl-2 family proteins (Day et al. 2008; Reed et al. 1996; Petros et
al. 2004). The BH3 domain of Puma is amphipathic and alpha-helical in structure (Day
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et al. 2008; Nakano & Vousden 2001; Yu et al. 2001). It binds directly to anti-apoptotic
proteins, such as Bcl-xl, and has been shown to bind all the anti-apoptotic proteins with
similar strength (Chen et al. 2005; Day et al. 2008; Gautier et al. 2011; Kuwana 2005).
The BH3 domain of Puma has also been shown to directly interact with the pro-apoptotic
protein, Bax (Cartron et al. 2004; Du et al. 2011; Gallenne et al. 2009; Yee & Vousden
2008; Zhang et al. 2009; Steckley et al. 2007), although others have presented contrary
evidence (Kuwana et al. 2005; Ming et al. 2006; Gautier et al. 2011; Willis et al. 2007).
The sequence and structure of the BH3 domain in Puma are well-documented, although
its ability to directly interact with the multi-domain pro-apoptotic Bcl-2 protein, Bax, and
the physiological significance of this interaction are still in question.
In our analysis of the Puma sequence, we identified the BH3 domain of Puma in
its anticipated location and with the same well-documented structural features we
expected (Figure 6). We also identified a more novel region on the Puma protein: a
putative mitochondrial-localization sequence at its c-terminus. In our analysis, we
discovered a highly-conserved sequence that runs from approximately amino acids 165185 at the c-terminus of the Puma protein (Figure 6). It is alpha-helical in structure and
primarily consists of hydrophobic amino acids (Figure 6). This group of hydrophobic
amino acids is flanked on either side by a few basic amino acids (Figure 6), similar to the
trans-membrane domain of Bcl-xl identified by Kaufmann et al. (2003). In Bcl-xl, this
region is responsible for targeting the protein specifically to the mitochondria (Kaufmann
et al. 2003). Others have proposed that something in the c-terminal region of Puma may
be responsible for localization of the protein, but the sequence and structure of this region
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have not been well-defined (Nakano & Vousden 2001; Yee & Vousden 2008; Yu et al.
2001; Yu & Zhang 2009).
We and others have previously demonstrated that a variety of apoptotic stimuli
induce Puma expression and localization to the mitochondrial outer membrane, and that
ectopically expressed Puma protein also displays this characteristic localization (Nakano
& Vousden, 2001; Steckley et al. 2007; Yee & Vousden 2008; Yu & Zhang 2009). Here,
we have identified a highly-conserved, hydrophobic, alpha-helical region at the cterminus of Puma (Figure 6). This region resembles the mitochondrial-localization
region of Bcl-xl (Figure 6; Kaufmann et al. 2003) and likely has a similar function in the
Puma protein.
Most of the Bcl-2 family members contain c-terminal membrane-localization
sequences, and it is unlikely that the prevalence of membrane-localization sequences
among the Bcl-2 family members is merely coincidental. Indeed, the mitochondrial outer
membrane has been shown to play an essential role in many Bcl-2 family member
interactions (Bogner et al. 2010; Jeong et al. 2004; Lalier et al. 2007; Lindsay, J. et al.
2011). The cytoplasmic conformations of the Bcl-2 family members Bcl-xl and Bax
discourage protein interactions and make it difficult for other proteins to interact with
them until they change to their membrane-anchored conformation (Jeong et al. 2004;
Lalier et al. 2007). Other BH3-only proteins, Bid and Bad, require interaction with
membranes in order to interact with multi-domain pro-apoptotic proteins (Lindsay, J. et
al. 2011). If Puma is able to specifically localize to the mitochondria, it may aid in its
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ability to interact with other Bcl-2 family members and may help to explain the efficacy
of Puma as a pro-apoptotic protein.

4.2 – Puma mitochondrial localization is regulated by a c-terminal targeting region
but not its BH3 domain or Bcl-2 family interactions
Our lab has previously shown that endogenous Puma localizes to the
mitochondria in response to oxidative stress in neuronal cells (Steckley et al. 2007).
Here, we have demonstrated that GFP-Puma (WT) displays a distinct cellular localization
pattern (Figure 8) and that it co-localizes with both Mitotracker ® Red CMXRos stain
and the mitochondrial protein, Tomm-20 (Figures 9 and 10). These results are in
agreement with other studies that have shown that ectopically expressed Puma localizes
to the mitochondria (Nakano & Vousden 2001; Yee & Vousden 2008; Yu et al. 2001; Yu
& Zhang 2009). However, the region of the Puma protein responsible for its localization
has not been well-defined in the literature.
In order to investigate the role of Bcl-2 family protein interactions in the
localization of Puma, we synthesized a tat-peptide designed to target Puma's BH3
domain. The BH3 domain is well established as the site for the interactions between
Puma and other Bcl-2 family members (Day et al. 2008; Reed et al. 1996; Petros et al.
2004). A peptide designed to mimic the Hα1 region of Bax has been shown to bind to the
BH3 domain of Puma and interfere with the interaction between Puma and Bax (Cartron
et al. 2004; Lalier, 2007). A mutation at amino acid residue 33 of this peptide from
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aspartate to alanine has been shown to abrogate its binding to the Puma-BH3 domain
(Cartron et al. 2004; Lalier et al. 2007). We synthesized Tat-fused Bax-Hα1 and BaxHα1(D33A) peptides to determine whether Puma interactions with other Bcl-2 family
proteins are required for its mitochondrial localization. In our studies with these
peptides, we found that Puma maintained its characteristic cellular localization even
when its interactions with other Bcl-2 family members were blocked by the Bax-Hα1 tatpeptide (Figure 5). These results suggest that Bcl-2 family member interactions are not
necessary for the mitochondrial-localization of Puma. This is in agreement with previous
observations from our lab that Puma maintains its mitochondrial-localization in neurons
cultured from Bax knockout mice (Steckley et al. 2007).
Consistent with these findings, we determined that the BH3 domain is not
necessary for Puma's mitochondrial-localization. In our examination of the localization
of the GFP-Puma mutants, we found that, although deletion of the BH3 domain did
abrogate Puma's ability to bind to the Bcl-2 family members, Bcl-xl and Bax (Figures 13
and 15), it had no affect on the localization of Puma (Figure 8). The variant of GFPPuma without its BH3 domain also retained its ability to co-localize with both
Mitotracker ® Red CMXRos stain and Tomm-20 (Figures 9 and 10). Taken together,
these experiments show that neither its BH3 domain, nor BH3 domain-mediated Bcl-2
family member interactions, are necessary for the mitochondrial-localization of Puma.
Instead, our results indicate that a distinct region at the c-terminus of Puma is
responsible for its mitochondrial-localization. We found that GFP-Puma (1-160), the
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variant missing its c-terminus, did not show the punctate localization characteristic of the
Puma protein; instead it showed diffuse fluorescence, similar to the pattern seen in cells
expressing the GFP plasmid (Figure 8). Although deletion of the c-terminus did not
affect Puma's ability to bind to other Bcl-2 family members (Figures 13 and 15), it
abrogated the co-localization of Puma with both Mitotracker ® Red CMXRos stain and
Tomm-20 (Figures 9 and 10). In contrast, the GFP-Puma variant consisting of only the cterminus of Puma, GFP-Puma (151-193), displayed a localization pattern consistent with
wild-type GFP-Puma protein (Figure 8). Although this variant was unable to bind to Bclxl or Bax (Figures 13 and 15), it was able to co-localize with both Mitotracker ® Red
CMXRos stain and Tomm-20 (Figures 9 and 10). These data confirm that the BH3
domain and BH3 domain-mediated Bcl-2 family member interactions are not necessary
for the mitochondrial-localization of Puma; they indicate that instead, a distinct cterminal region is responsible for Puma's localization. This is consistent with our earlier
finding that Puma contains an important region at the c-terminus of the protein (Figure 6)
and also consistent with some of the initial findings about the Puma protein. Upon its
discovery, Nakano and Vousden (2001) looked at different transcriptional variants of
Puma, including the truncated Puma-δ and Puma-γ, both of which are missing the cterminus of the full-length protein. They found that these Puma variants were unable to
induce apoptosis or localize to the mitochondria (Nakano & Vousden, 2001).
Although the majority of GFP-Puma puncti appear to co-localize with
mitochondria, in both the Mitotracker ® Red CMXRos stain and Tomm -20
immunofluorescent staining, there appear to be some GFP-Puma puncti that are not c-
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localized with mitochondria (Figures 9 and 10). Some of these puncti may be protein
aggregates caused by over-expression of the proteins. Another explanation is that the cterminus may not direct the Puma protein specifically to the mitochondrial membrane,
but may be a more general membrane-localization sequence that also directs Puma to
other cellular membranes, such as the endoplasmic reticulum or the lysosomal
membranes. The localization sequences of some Bcl-2 family members, such as Bcl-2,
have been shown to direct the protein to general membranes rather than specifically to the
mitochondria (Kaufmann et al. 2003). However, the membrane-localization sequence at
the c-terminus of Puma appears more similar to the mitochondrial-specific localization
sequence seen in Bcl-xl (Figure 6; Kaufmann et al. 2003). Our lab has also previously
demonstrated that endogenous Puma localizes to the mitochondria in neurons undergoing
oxidative stress (Steckley et al. 2007). Altogether, these data suggest the at least the
majority of Puma localizes to the mitochondria in neuronal apoptosis.
Because the mitochondrial outer membrane has been shown to play such a crucial
role in the interactions of Bcl-2 family proteins (Bogner et al. 2010; Jeong et al. 2004;
Lalier et al. 2007; Lindsay, J. et al. 2011), the ability of the Puma c-terminus to localize
the majority of Puma protein to the mitochondrial membrane might help to explain the
efficacy of Puma as a pro-apoptotic protein. The fact that the GFP-Puma protein without
an intact c-terminus appears unable to localize to the mitochondria may also explain its
inability to induce apoptosis.
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4.3 – Both the BH3 domain and c-terminal mitochondrial-localization region of
Puma are required for Puma-mediated cell death and apoptosis
Although we did not find that the BH3 domain or BH3 domain-mediated Bcl-2
family interactions were important for the mitochondrial-localization of Puma, they do
appear to be necessary for the full apoptotic function of the protein. Here we found that
GFP-Puma (ΔBH3) and GFP-Puma (151-193), the variants unable to bind to the Bcl-2
family members, Bcl-xl and Bax (Figures 13 and 15), were unable to induce apoptosis
(Figures 11 and 12). We also found that blocking the ability of Puma to bind to Bcl-2
family members with a tat-fused Bax-Hα1 peptide abrogated its apoptotic activity (Figure
5). In accordance with these results, we found that the BH3 domain of Puma is required
for Puma-induced apoptosis. Deletion of the BH3 domain eliminated the protein's ability
to induce apoptosis (Figures 11 and 12). Altogether, the results of these experiments
suggest that Puma requires both its BH3 domain and BH3 domain-mediated Bcl-2 family
member interactions in order to induce apoptosis. These conclusions are in agreement
with others who have shown that Puma mediates apoptosis through its interactions with
other Bcl-2 family members, and that the BH3 domain of Puma is the site of its
interactions with both pro- and anti-apoptotic Bcl-2 family members (Cartron et al. 2004;
Day et al. 2008; Du et al. 2011; Gallenne et al. 2009; Reed et al. 1996; Petros et al. 2004;
Steckley et al. 2007; Yee & Vousden 2008; Zhang et al. 2009). Because the BH3domain of Puma is believed to be the site of its interactions with other Bcl-2 family
members, it makes sense for this domain to be of particular importance in the induction
of apoptosis by Puma (Cartron et al. 2004; Day et al. 2008; Reed et al. 1996; Petros et al.
2004).
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Our results suggest that Puma is able to activate Bax and promote apoptosis
through both the indirect and the direct activation models. We have found that Puma is
able both to bind to the anti-apoptotic Bcl-xl and to bind directly to Bax (Figures 13 and
15). This may help to reconcile the current controversy surrounding the activation of Bax
by Puma. Many studies have shown that Puma can interact directly with Bax to activate
it (Cartron et al. 2004; Du et al. 2011; Gallenne et al. 2009; Melino et al. 2004; Ren et al.
2010; Steckley et al. 2007; Yee & Vousden 2008; Zhang et al. 2009), while others have
shown that apoptosis can occur without a direct interaction between Puma and Bax
(Gautier et al. 2011; Kazi et al. 2011; Kuwana et al. 2005; Ming et al. 2006; Willis et al.
2007). Our results indicate that Puma is able to promote apoptosis through both models
of Bax activation (Figures 13 and 15); perhaps Puma follows the indirect model if direct
interaction with Bax is blocked in some way. Puma may even preferentially follow
different models dependent on cell type or death stimulus. This flexibility or redundancy
may help to explain the efficacy of Puma as a pro-apoptotic protein.
Interestingly, our results indicate that the BH3 domain and BH3 domain-mediated
Bcl-2 family interactions are not the only requirements for Puma's full apoptotic activity.
We examined the role of the c-terminus in the induction of apoptosis and found that the
c-terminus of Puma is also required for the apoptotic function of the protein. GFP-Puma
(1-160), the variant with an intact BH3 domain but missing the c-terminus, was unable to
induce apoptosis (Figures 11 and 12). These results are consistent with other findings
that the full-length Puma protein is required for its apoptotic activity (Nakano & Vousden
2001; Yu et al. 2003). If, as our earlier data indicates, this region is indeed responsible
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for the cellular localization of the protein, then it appears that cellular localization plays
an essential role in the apoptotic function of Puma. Most of the Bcl-2 family members
contain c-terminal membrane-localization sequences, and it is unlikely that the
prevalence of membrane-localization sequences among the Bcl-2 family members is
merely coincidental. It is possible that these proteins localize to membranes in order to
increase the chances of coming near enough to each other to interact. Additionally, some
of the Bcl-2 family members, such as Bax, exist in a cytoplasmic conformation that might
inhibit binding by other proteins (Lalier et al. 2007). Others, such as Bcl-xl, may form
homodimers in the cytoplasm, possibly occupying their binding sites until they associate
with a membrane (Jeong et al. 2004). These last two possibilities would require at least
some of the Bcl-2 family members to associate with membranes before they could bind to
other proteins. Indeed, the BH3-only proteins Bid and Bad require localization to the
mitochondrial outer membrane in order to induce apoptosis (Bogner et al. 2010; Lindsay,
J. et al. 2011). Given the importance of membrane targeting among the other Bcl-2
family members, it is perhaps unsurprising that the c-terminal localization sequence of
Puma is required for its apoptotic function.
Overall, our findings demonstrate that neither the BH3 domain, nor the c-terminal
mitochondrial-localization region of Puma are sufficient to induce apoptosis without the
other. GFP-Puma (1-160) does not localize to the mitochondrial outer membrane
(Figures 9 and 10) and is unable to induce apoptosis (Figures 11 and 12), even though its
intact BH3 domain is able to bind to Bcl-xl and Bax in vitro (Figures 13 and 15). On the
other hand, GFP-Puma (ΔBH3) cannot bind to Bcl-xl or Bax (Figures 13 and 15) and is
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unable to induce apoptosis (Figures 11 and 12), even though its intact c-terminus
localizes the protein to the mitochondria (Figures 9 and 10).
One possible explanation for the necessity of both regions of the Puma protein is
that they both play a role in the ability of Puma to interact with Bcl-2 family members in
situ. This is perhaps most obvious in the case of Puma's interaction with Bcl-xl. Unlike
the other anti-apoptotic Bcl-2 family members, Bcl-xl localizes specifically to the
mitochondria (Kaufmann et al. 2003; Lindsay et al. 2011). It is arguably one of the most
important anti-apoptotic proteins and has also been shown to play a particularly important
role in neuronal apoptosis (Motoyama et al. 1995; Ming et al. 2006). The BH3-domain
of Puma is understandably important for binding to Bcl-xl, as it is the domain generally
accepted to be the location of this interaction (Day et al. 2008; Reed et al. 1996; Petros et
al. 2004). When we examined the ability of the various GFP-Puma proteins to bind to
Bcl-xl in homogenous cell lysate, we found that the BH3 domain, but not the c-terminus
of Puma was required to bind to Bcl-xl (Figure 13). In these conditions, where the
cellular contents are homogenously mixed, cellular localization does not affect protein
interactions with the same importance as in intact cells. However, when we examined the
ability of the GFP-Puma variants to co-localize with Bcl-xl in situ, we found that the cterminus of Puma was essential for co-localization of the two proteins (Figure 14). In
combination, these results indicate that the BH3 domain of Puma is the location of the
bond between Puma and other Bcl-2 family members, while the c-terminus is responsible
for ensuring the cellular co-localization of the proteins necessary for their interaction in
situ. Whether this co-localization is important solely because the proteins must be near to
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each other to interact, or if it is also vital that Puma interacts with the mitochondrial
membrane in order for the interactions with other Bcl-2 family members to take place,
requires further study. A large quantity of evidence is accumulating for the importance
of membranes in the interactions among various Bcl-2 family members, including Bid,
Bad, Bax, and Bcl-xl (Bogner et al. 2010; Lalier, L. et al. 2007, Lovell, J.F. et al. 2008;
Roucou et al. 2002; Yethon et al. 2003), so it would not be surprising if the interactions
between Puma and the mitochondrial membrane aided its interactions with other Bcl-2
family members as well.
Another possible explanation for the importance of the c-terminus is that Puma
may bind to the pro-apoptotic protein, Bax, in the cytoplasm and then bring it to the
mitochondria where it is able to continue the apoptotic process. In this scenario, the
mitochondrial-localization region of Puma would be required for both proteins to
translocate to the mitochondria. This explanation is supported by data previously shown
by our lab that Puma was required for Bax to localize at the mitochondria in neuronal
apoptosis (Steckley et al. 2007). In the present study, we did not find that the c-terminus
of Puma was required to bind to Bax in homogenous cellular lysate. However, similar
results were seen in the co-immunoprecipitation experiment with Puma and Bcl-xl, and
these results were later explained upon examination of the co-localization of the proteins
in situ. Since we and other have shown that Bax localizes to the mitochondrial outer
membrane (Antonsson et al. 2000; Carton et al. 2003; Gardia et al. 2004; Lalier et al.
2007; Nechustan et al. 1999; Steckley et al. 2007), it is likely that, as with Pumas ability
to bind to Bcl-xl, the c-terminus of Puma is not required to bind Bax in cellular lysate but
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is required to bind Bax in intact cells where cellular localization is of greater importance.
Future studies could use fluorescent or bioluminescent resonance energy transfer (FRET
or BRET) to better examine the ability of Puma to functionally interact with Bax, Bcl-xl,
and other Bcl-2 family members in situ.
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Chapter 5 – Summary and Conclusions
In this work we have identified two key regions of Puma: its BH3 domain and its
c-terminal mitochondrial-localization region. We have found both of these regions to be
necessary for interactions with other Bcl-2 family members and for full apoptotic
function of the protein. We have also elucidated several factors that help to explain the
efficacy of Puma as a pro-apoptotic protein: its ability to localize to the mitochondrial
membrane, a key membrane in Bcl-2 family-mediated apoptosis; its ability to co-localize
and interact with the important anti-apoptotic protein, Bcl-xl; and its ability to activate
Bax through both the indirect and the direct models. The efficacy of Puma as a proapoptotic protein appears to rely on both an intact BH3 domain and c-terminal
mitochondrial-localization region.
We believe that further investigation of these two regions on the Puma protein
will yield even more information about the unique apoptotic efficacy of Puma, and that
further understanding of this key protein will contribute to our understanding of Bcl-2
family regulated apoptosis. Since the intrinsic, Bcl-2 family regulated, apoptotic pathway
has been shown to play an important role in many chronic and acute neuronal pathologies
(Engel et al. 2011; Higgins et al. 2010; Kotipatruni et al. 2011; Nitatori et al. 1995;
Portera-Cailliau et al. 1995; Steckley et al. 2007; Vila & Przedborski 2003), knowledge
of critical regions on the Puma protein may also provide targets for the treatment of these
conditions.
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Appendices
Table 1 - Restriction Enzyme Digest

Reagents
Reagent
Enzyme 1
Enzyme 2
DNA
10x NEBuffer
Dnase- Rnase-free water
Total

Volume (μl)
1.00
1.00
5.00
5.00
38.00
50.00

Restriction Enzymes
Plasmids

Enzymes

GFP-Puma (WT and ΔBH3)

Kpn I and Bam H1

GFP-Puma (1-160 and 151-193)

Eco RI and Sal I
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Table 2 - Ligation

Reagents
Reagent
Vector
Insert
Ligase Buffer
T4 DNA Ligase
Dnase- Rnase-free water
Total

Volume (μl)
1.0
5.0
2.0
1.0
11.0
20.0
Ligation Buffers

Plasmids

Buffer

GFP-Puma (WT and ΔBH3)

NEBuffer 2 (New England Biolabs
#B7002S)

GFP-Puma (1-160 and 151-193)

NEBuffer 3 (New England Biolabs #
B7003S)
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Table 3 – Polymerase Chain Reaction Cloning

Qiagen Reagents for PCR Cloning
Reagent
Buffer
Mg
dNTP
Q
Forward primer
Reverse primer
Qiagen Taq
High Fidelity Phusion Taq
DNA
Dnase- Rnase-free water
Total

Volume (μl)
5.0
4.0
4.0
10.0
4.0
4.0
1.0
0.5
1.0
17.5
50.0

Cycling Conditions
1.
2.
3.
4.
5.
6.
7.

94°C for 4 minutes
94°C for 15 seconds
55°C for 15 seconds
68°C for 30 seconds
Repeat #2-4 for 35 cycles
72°C for 10 minutes
10°C indefinitely
Primers

Plasmid
Puma (1-160)

5'-sense-3'

3'-antisense-5'

GATCGAATTCTTGATGGCCC CTAGCTGCAGCTGCTCCTCT
GCGCACGC
GGTCTCCG

Puma (151-193) CATCGAATTCCAGTACGAGC CTAGGTCGACCTAATTGGGC
GGCGGAGA
TCCATCTC
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Table 4 – Summary of plasmid properties.

Plasmid

Localize at Apoptotic
mitochondria

IP with
Bcl-xl

Co-localize
with Bcl-xl

IP with
Bax

GFP

-

-

-

-

-

GFP-Puma (WT)

+

+

+

+

+

GFP-Puma (ΔBH3)

+

-

-

+

-

GFP-Puma (1-160)

-

-

+

-

+

GFP-Puma (151-193)

+

-

-

+

-
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Table 5 – Peptide sequences.

Peptide
Bax-Hα1

Sequence
Ac-YGRKKRRQRRRSEQIMKTGAFLLQGFIQDRA-NH2

Bax-D33A Ac-YGRKKRRQRRRSEQIMKTGAFLLQGFIQARA-NH2
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